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Background: Hepatitis C virus (HCV) infection is the most prevalent bloodborne viral 
infection nationally. Injection drug use is the most commonly reported mode of transmission 
and incident cases of acute HCV infection have more than quadrupled between 2010 and 
2018. This increase is primarily attributed to shared injection practices associated with the 
nation’s opioid epidemic. Effective treatment for HCV emerged in late 2013 via the advent of 
direct acting antiviral (DAA) agents, but treatment rates remain exceedingly low among 
PWID. Our understanding of barriers to treatment among PWID is based largely on studies 
conducted in the pre-DAA era when treatment itself was a barrier. Our study aims to 
evaluate how HCV treatment uptake has changed since the availability of DAAs among a 
community-based cohort of current and former PWID with the goal to better understand 
potential barriers to DAAs and subgroups of PWID at-risk of not accessing treatment today. 
Methods: We conducted our research using data from the ALIVE (AIDS Linked to the 
IntraVenous Experience) study, a community-based cohort of PWID, ongoing since 1988, 
located in Baltimore, MD. Aim 1 identified clusters of low HCV treatment penetration in 
Baltimore, MD at three time-points: the interferon-era (2006-2007), early DAA-era (2015-
2016) and later DAA-era (2017-2018). Subsequently, we evaluated whether these areas are 
best explained by neighborhood deprivation or individual characteristics. Aim 2 evaluated 
differences in knowledge of HCV and its treatment by HCV and HIV infection status and 
other individual-level factors. We used a subset of questions from a 17-question survey, 
performed at enrollment among participants enrolled 2015-2018 to create three HCV 
knowledge subscales: transmission, natural history, and treatment. Aim 3 evaluated 
temporal changes in HCV treatment uptake from 2011-2019 to identify groups with 
persistent low treatment uptake and associated correlates. 
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Results: In our first aim, we identified clusters of HCV viremia in two of the three time-
periods. The first, was a single cluster in the interferon-era (2006-2007) and then two 
clusters in the early DAA-era (2015-2016). No cluster was identified in the late DAA-era. 
While characterizing these clusters, we found that neighborhood deprivation was the 
primary predictor of clustering in both eras. In Aim 2, we found that, overall, HCV knowledge 
was high among these PWID but there was variability in treatment knowledge. We found 
higher treatment knowledge was associated with being HCV mono-infected, compared to 
HCV-negative PWID and among participants who were aware of their HCV diagnosis before 
completing the HCV assessment compared to those diagnosed through testing at the ALIVE 
study. Finally, in Aim 3 we found that treatment uptake improved greatly after DAAs became 
available. Improved treatment uptake in the early DAA-era was associated with older age, 
healthcare utilization, and having cirrhosis. Healthcare utilization and high frequency drug 
use were the predictors of treatment uptake in the late DAA-era. 
Conclusions: We found that, overall, treatment uptake had improved between the interferon 
and DAA eras but was slower in areas of higher neighborhood deprivation. Our failure to 
identify clusters of HCV treatment need in the late DAA-era suggests that treatment has 
likely penetrated even the most marginalized areas. We evaluated changes in HCV 
knowledge, a known individual-level barrier in the interferon-era and found variability in 
treatment knowledge. Results suggest that information regarding treatment is probably 
communicated when a person is diagnosed or at some point afterwards. However, results 
also showed that residual misinformation regarding interferon-based therapies persist today, 
particularly knowledge of side effects, pill burden, and treatment duration. Subgroups at-risk 
of poor treatment uptake today were individuals not engaged in healthcare or injecting drugs 
with high frequency. These subgroups might be difficult to reach and targeted approaches 





Shruti H. Mehta, PhD, MPH (Advisor) 
Deputy Chair, Department of Epidemiology  
Professor 
Johns Hopkins Bloomberg School of Public Health 
 
Greg Lucas, MD, PhD 
Department of Medicine 
Professor 
Johns Hopkins School of Medicine 
 
Becky Genberg, PhD, MPH (Co-Advisor) 
Department of Epidemiology 
Associate Professor 
Johns Hopkins Bloomberg School of Public Health 
 
Renee Johnson, PhD, MPH 
Department of Mental Health 
Associate Professor 




David Celentano, ScD, MHS  
Charles Armstrong Chair in Epidemiology, Department of Epidemiology 
Professor 
Johns Hopkins Bloomberg School of Public Health 
 
Danielle German, PhD, MPH  
Health, Behavior, and Society 
Associate Professor  







First and foremost, I want to thank my advisor, Dr. Shruti Mehta, who has been incredibly 
supportive throughout this entire process. She has been a constant inspiration for me to be 
a better scientist and provided both invaluable mentoring and guidance. Shruti has a high 
bar and striving to meet it, has, without question, raised the quality of my work and the 
standard that I hold for myself to in academic and non-academic endeavors. Everyone who 
takes second year doctoral seminar knows not to use Calibri font or default colors, but I 
have benefited from all of the additional mentorship and support, which was instrumental to 
my success.    
I am also extremely grateful to Dr. Becky Genberg, my co-advisor, who has been a constant 
support over the last three years. She has been influential in my growth as a graduate 
student and her advice has helped crystallize my research and the impact that I hope my 
work will achieve. I am also grateful for Dr. Frank Curriero, a member of my thesis 
committee, for his feedback and guidance. He challenged me to think critically about the 
public health implications of my work, which only strengthened my skills as a public health 
researcher. Additionally, I would like to thank Dr. Michael Desjardins for his direction and 
help, which is undeniably raised the quality of my research. Finally, I would also like to thank 
the faculty members who served on my exam committee, Dr. David Celentano, Dr. Gregory 
Kirk, Dr. Greg Lucas, and Dr. Danielle German. In particular, I would like to thank Dr. Renee 
Johnson and Dr. Sabriya Linton, both members of my exam committee, whose feedback 
and encouragement have been invaluable.  
This work would not have been possible without participants and staff from the ALIVE study. 
In particular, I would like to thank Jacquie Astemborski who was always there to help and 
vi 
 
listen not matter how busy she was, or how trivial or mundane the problem. Her willingness 
to explain both simple and complicated analyses was extremely helpful.  
In the department of Epidemiology, I would like to thank all of the members of SORT, 
especially Emma Moynihan, for being my partner-in-crime in all of our projects, and Katie 
Overby for all of the laughs, as well as, Melissa Marx and Emily Gurley, who have not only 
taught me about applied epidemiology but also helped frame the type of work I hope to do in 
the future. I also benefited from the two years on the T32 HIV training grant, where I learned 
about different aspects of HIV-related research from fellow trainees and faculty. I would also 
like to thank Fran Burman and Matt Miller for all of their support. I am also thankful for the 
members of my doctoral cohort, especially, Dr. Esther Kim, Dr. Gideon Loevinsohn. Dr. Kate 
Leifheit, and Athalia Christie, as well as, Daniel Antiporta Penaloza, and Molly Jung. I could 
not have asked for better friends for this journey.       
There are also many people who have helped me get here. I would like to acknowledge Dr. 
Lisa Bond and my MPH advisor Dr. Rickie Brower for pushing me to do a PhD, before I even 
knew I wanted to do one. Lisa also wrote the initial grant to implement HCV testing in 
primary care, where I discovered my passion for HCV. Additionally, I would like to thank Dr. 
Deborah Holtzman and Anne Moorman, who were my biggest cheerleaders throughout the 
process of applying to schools and throughout the program. Their patience, guidance, and 
support were invaluable. Lastly, I am grateful for my college rowing coach, Kevin Sauer. 
Kevin was the person that pushed me to reach my full potential as a rower. He knew just 
how to coach each athlete to bring the best out of them. He did not compliment often, so 
when he finally did, it was all the more meaningful. Through the toughest times of this 
program, I fell back on some of the encouragements he told me as an athlete.    
vii 
 
Finally, I dedicate this dissertation to my parents, Rena and Gary Coyle, who made my 
education a family priority, often at great sacrifice. This degree is the return on their 










Table of Contents viii 
  
List of Tables x 
  
List of Figures xi 
  
Chapter 1. Introduction and Background 1 
   Specific Aims 1 
   Hepatitis C Virus (HCV) 4 
   Natural History and Symptomatology 4 
   HCV Diagnostics and Liver Fibrosis Staging 5 
   HCV Transmission and Prevention 8 
   Treatment Modalities 9 
        Interferon Era of HCV Treatment 10 
        Direct Acting Antiviral (DAA) Era of HCV Treatment 11 
   HCV Treatment among Key Populations 13 
        HCV Treatment among Persons with HIV/HCV Coinfection 13 
        HCV Treatment among Persons who Inject Drugs (PWID) 14 
   Epidemiology of HCV and Calls for HCV Elimination 14 
   Progress towards HCV Elimination in the United States 16 
   HCV and PWID in Baltimore, Maryland 17 
   AIDS Linked to the Intravenous Experience (ALIVE) Study 17 
   Conceptual Framework 20 
   Summary 21 
   References 22 
  
Chapter 2. Geographic variation of HCV treatment penetration and associated 
characteristics in the interferon and direct acting antiviral eras among people who 
inject drugs (PWID) in Baltimore, Maryland 29 
   Abstract 30 
   Introduction 32 
   Methods 34 
   Results 39 
   Discussion 41 
   References 45 
  
Chapter 3. Assessing knowledge of HCV and direct acting antivirals among people who 
inject drugs (PWID) by HIV and HCV status, in Baltimore, Maryland 54 
   Abstract 55 
ix 
 
   Introduction 57 
   Methods 58 
   Results 62 
   Discussion 65 
   References 69 
  
Chapter 4. Evaluating temporal trends and changes in predictors of HCV treatment 
uptake in the interferon and direct acting antiviral eras among people who inject drugs 
(PWID) in Baltimore, Maryland 79 
   Abstract 80 
   Introduction 82 
   Methods 84 
   Results 88 
   Discussion 91 
   References 95 
  
Chapter 5. Conclusions 105 
   Summary of Findings 105 
   Strengths and Limitations 108 
   Public Health Implications and Recommendations for Future Research 110 
   Summary 112 
   References 114 
  





List of Tables  
  
Chapter 1. Introduction and Background  
     Table 1. Criteria for HCV Antibody Testing Based on 1998 CDC HCV Testing Recommendations 9 
  
Chapter 2. Spatial Distribution and Clustering of HCV Treatment Need  
  
Table 1. Individual and neighborhood characteristics of HCV-antibody ALIVE participants by HCV 
RNA status, Baltimore City and Baltimore County, 2006-2018 49 
Table 2. Participant and neighborhood-level correlates of membership in a cluster of elevated HCV 
treatment need among ALIVE participants, Baltimore City and Baltimore County, 2006-2007 and 
2015-2016 50 
Supplemental Table 1. Characteristics of purely spatial and space-time cluster detection, Baltimore 
City, 2006-2007, 2015-2016 51 
  
Chapter 3. Knowledge of HCV by HIV Status  
  
Table 1. Characteristics of 846 ALIVE participants who completed an HCV knowledge survey by HCV 
and HIV status, Baltimore, MD, 2015-2018  72 
Table 2. Results of a 17-item HCV knowledge scale among 826 ALIVE participants, Baltimore, MD, 
2015-2018 73 
Table 3. Correlates of high HCV transmission knowledge among participants of ALIVE study by HIV 
and HCV status, Baltimore, MD, 2015-2018  74 
Table 4. Correlates of high HCV natural history knowledge among participants of ALIVE study by HIV 
and HCV status, Baltimore, MD, 2015-2018  75 
Table 5. Correlates of high HCV treatment knowledge among participants of ALIVE study by HIV and 
HCV status, Baltimore, MD, 2015-2018    76 
Supplemental Table 1a. Proportion of participants with HIV/HCV coinfection with high HCV knowledge 
by HIV viral suppression 77 
Supplemental Table 1b. Proportion of participants with high knowledge by HCV diagnosis and 
treatment status  77 
Supplemental Table 2. Correlates of high HCV treatment knowledge among HCV-infected participants 
by awareness of HCV status upon study entry 78 
  
Chapter 4. Temporal Changes in HCV Treatment Uptake, 2011-2019  
     
Table 1. Characteristics of 1,146 HCV-antibody positive participants by self-reported HCV treatment 
status anytime from 2011-2019 99 
Table 2. Characteristics of 488 participants with chronic HCV infection who self-reported HCV 
treatment per year 100 
Table 3. Correlates of HCV treatment uptake by HCV treatment time-period among ALIVE 
participants, Baltimore MD, 2011-2019 101 
Supplemental Table 1. Correlates of HCV treatment uptake by ALIVE cohort in the later DAA-era, 





List of Figures  
  
Chapter 1. Introduction and Background  
Figure 1. Conceptual framework 20 
  
Chapter 2. Spatial Distribution and Clustering of HCV Treatment Need  
  
Figure 1. Spatial distribution of HCV treatment need by Census tract among ALIVE 
participants using Empirical Bayes Smoothing, Baltimore City and Baltimore County, 2006-
2007, 2015-2016, 2017-2018 52 
Figure 2a. Unadjusted purely spatial cluster of HCV treatment need in Baltimore City and 
Baltimore County, 2006-2007 53 
Figure 2b. Unadjusted space-time clusters of HCV treatment need in Baltimore City and 
Baltimore County, 2015-2016 53 
     
Chapter 4. Temporal Changes in HCV Treatment Uptake, 2011-2019  
  
Figure 1. Cumulative HCV treatment uptake among ALIVE participants, Baltimore, MD 
2011-2019 103 
Figure 2. Annual rate of HCV treatment uptake among ALIVE participants, Baltimore MD, 
2011-2019 103 
Supplemental Figure 1. Cumulative HCV treatment uptake among ALIVE participants by 
recruitment cohort, Baltimore MD, 2015-2019 104 
Supplemental Figure 2. Annual rate of HCV treatment uptake among ALIVE participants by 






Chapter 1. Introduction and Background 
 
Specific Aims 
With 4.1 million people having been infected with the hepatitis C virus (HCV), HCV is the 
most common bloodborne viral infection in the United States. Moreover, there is growing 
concern because HCV incidence has increased more than 4.1-fold since 2010, with most of 
the cases among young people who inject drugs. Furthermore, HCV-related mortality is also 
increasing among an aging population some of whom were PWID who were infected 
decades ago.  
 
New treatment options, direct acting antivirals (DAA), became available in late 2013. These 
require only a single pill per day, for less than 12 weeks with high cure rates. This replaced 
interferon-based therapies as the standard of care, which included weekly injections, high 
pill burden for 48 weeks, and cure rates of about 50%. Because of the growing burden of 
HCV incidence and mortality, and availability of DAAs, both the World Health Organization 
and National Academies of Sciences, Engineering, and Medicine released two goals to 
achieve HCV elimination by 2030. They are to decrease HCV incidence by 90% and HCV-
related mortality by 65%.  
 
Since then, HCV treatment uptake has increased remarkably, but remains low among some 
subgroups including PWID. Barriers to HCV treatment before DAAs were well understood, 
with the primary barrier being side effects related to the treatment itself. Additional research 
is needed to understand the structural and individual barriers preventing PWID from being 
treated today, in the era of DAA-based therapy. It is particularly important to understand 
differences across key subgroups to provide insight into the efforts to universally expand 
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HCV treatment among PWID. To contribute to these efforts, we propose the following 
specific aims:  
 
Aim 1: To identify clusters of low HCV treatment penetration in Baltimore City and 
Baltimore County, Maryland and evaluate how these clusters have evolved over time. 
We will use serial cross-sectional data from the ALIVE study to explore the spatial 
distribution of HCV treatment need and identify statistically significant clusters of PWID with 
poor treatment uptake for three time-periods settings. These include the interferon-era 
(2006-2007), in which HCV treatment uptake was low, early in the availability of DAAs 
(2015-2016), and later in the availability of DAAs (2017-2018). Subsequently, we will 
examine how features of the underlying population and neighborhood deprivation explain 
the observed clustering. We hypothesize that clusters of persons who need HCV treatment 
will change over time and be areas with of high neighborhood deprivation. 
 
 Aim 2: To evaluate differences in knowledge of HCV and its treatment by HCV and 
HIV infection status and other individual-level factors. We will use cross-sectional data 
to determine the extent to which knowledge regarding HCV treatment has penetrated the 
PWID community and how it varies by both HCV and HIV status, and proximity to service 
locations, including substance use treatment facilities, where PWID could potentially receive 
HCV education. We will do this by analyzing data from ALIVE participants recruited into the 
community-based cohort of PWID from 2015-2018. Domains of interest included knowledge 
of HCV transmission, natural history, and treatment modalities. We hypothesize that HCV 
knowledge will highest among HIV/HCV coinfected compared to HCV mono-infected and 




Aim 3:  To compare temporal changes in HCV treatment uptake from 2011-2019 
among PWID and identify groups with persistent low treatment uptake and associated 
correlates. We will use longitudinal data to understand changes in HCV treatment uptake 
before and after the availability of DAAs among PWID in the ALIVE study. Furthermore, we 
will evaluate how barriers and facilitators of HCV treatment have changed over time and 
identify groups that have lower than expected treatment uptake today. We hypothesize that 
uptake will be highest among coinfected HIV/HCV PWID with HIV viral suppression and vary 
by age, and duration of drug use.   
 
We plan to nest these specific aims within the ALIVE (AIDS Linked to the IntraVenous 
Experience) study, a community-based cohort of former and current PWID, in Baltimore 
City, ongoing since 1988. Baltimore is a unique setting in which to examine the changes in 
HCV treatment among PWID due to its longstanding population of people who inject heroin 
and high HCV prevalence and incidence among PWID. The expected outcomes of this 
study will be findings to inform local HCV elimination efforts on where and how to engage 




Hepatitis C Virus (HCV) 
Isolated in 1989, HCV is a small, enveloped, positive sense single-stranded RNA virus in the 
Flaviviridae family. It is comprised of a lipid envelope, two envelope proteins, and a 
nucleocapsid, which contains the viral genome that encodes the structural and non-
structural proteins of HCV. The structural proteins are used to form the capsid and two 
envelope proteins of future virions. The six non-structural proteins, NS2, NS3, NS4A, NS4B, 
NS5A, NS5B, form the replication complex that will make more positive single-stranded 
RNA, which will be packaged into viral particles with the structural proteins.  
HCV has a high amount of genetic heterogeneity. To date, eight genotypes and over 100 
subtypes have been discovered.1,2 Furthermore, once infected, intrapersonal mutation is 
common.2 There is substantial variation in the global distribution of genotypes. For example, 
genotype 1 is most common in North America and Europe, comprising 75% and 64% of all 
cases of HCV, respectively.3 Whereas, genotype 4 accounts for 65% of the infections in 
North Africa and the Middle East and more than one-third of the cases in the Asia-Pacific 
region are genotype 3.3 Given the heterogeneity of the virus itself and global epidemiology, 
a single, universal HCV vaccine has yet to be approved by the FDA. However, both 
prophylactic and therapeutic vaccine trials are underway.  
 
Natural History and Symptomatology  
Of those who develop acute HCV, between 55% and 85% will progress to chronic infection, 
which is defined as the persistence of HCV RNA in blood for at least 6-months.4,5 High rates 
of spontaneous clearance are associated with being female, white, a younger age at time of 
infection, low HCV viral load, abstinence from alcohol and injection drug use, HIV 
coinfection, and ILB28 genotype CC.4,6–11 Over the next 25-30 years, between 20% and 
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30% of those with chronic HCV will develop cirrhosis.4 Among those who develop cirrhosis, 
30% will develop hepatic decomposition over 10 years, which has a 5-year survival rate of 
50%, or develop hepatocellular carcinoma (1%-4% per year).4,12 However, HCV sequalae is 
impacted by a variety of host, viral, or environmental factors. For example, older age at 
infection, obesity, alcohol use, HIV coinfection, genotype 1, and high HCV viral load have 
been associated with accelerated progression of fibrosis.11–14 But encouragingly, studies 
have shown that liver damage, even cirrhosis, is reversible after a person is successfully 
treated for HCV.15,16  
HCV’s average incubation period is 14-84 days but can last up to 128 days.17 However, few 
individuals with acute HCV infection ever experience symptoms.11,18 If they do, symptoms 
are non-specific and include flu-like symptoms, abdominal pain, fatigue, nausea, and 
jaundice.4,11 As a result, early detection of HCV is very difficult. Most people become 
symptomatic decades after being infected when they begin to experience HCV-related 
morbidity. These patients may exhibit physical signs of chronic liver disease and 
decompensated cirrhosis, like jaundice, portal hypertension, esophageal varices, or 
ascites.19,20  
 
HCV Diagnostics and Liver Fibrosis Staging 
Initial screening for HCV infection is typically done with a serologic assay used to 
identify antibodies that indicate if a person has been exposed to HCV. The two 
serologic tests used in the United States are an enzyme immunoassay (EIA) and 
point-of-care rapid immunoassay. Sensitivity and specificity of the EIA test are 
roughly >98% and 100%, respectively.21 A pooled analysis found that the combined 
sensitivity of the point-of-care tests ranged from 86.2% to 99% but all had a 
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specificity of >99%.22 Among those with a reactive serologic test, a confirmatory molecular 
HCV RNA test is required to determine if the person has spontaneously cleared the virus, 
has active infection, or was a false positive.12,23 The real-time polymerase chain reaction 
(PCR) HCV RNA test is able to detect a minimum RNA level of 10-50 IU/mL, giving it good 
sensitivity. Additionally, the test’s specificity is 98%-99%.12 Commercial laboratories now 
offer reflexive HCV RNA testing, which enables the laboratory to automatically perform the 
confirmatory HCV RNA test on any reactive HCV serologic assay. This enables healthcare 
providers to disclose a confirmed HCV test result at a single visit, rather than over two with a 
second venipuncture. 
In 2013, the Centers for Disease Control and Prevention (CDC) updated their testing 
sequence.24 With the updated algorithm, persons that have a negative antibody test are not 
HCV infected, unless there is reason to believe the test was a false negative, like suspected 
acute infection or if the individual is immunocompromised.24 Positive HCV antibody and RNA 
tests indicate active, chronic, infection, and the person should be linked to HCV care.24 
Finally, an HCV positive antibody but negative HCV RNA test could indicate one of three 
things: successful cure, spontaneous clearance, or false positive.24 If indicated, a different 
antibody assay could be used to differentiate between past infection and a false positive 
test.24  
Once a person with chronic HCV infection is engaged in HCV care, staging of liver fibrosis is 
used to assess HCV-related morbidity.12 There are a number of scoring systems used to 
quantify liver fibrosis. One that is frequently used is the METAVIR score.25 It categorizes 
liver fibrosis into five stages of increasing severity: none (F0), mild (F1), moderate (F2), 
severe (F3), and cirrhosis (F4).26 A liver biopsy is the gold standard for directly evaluating 
liver fibrosis.27,28 However, biopsies are invasive and there are questions regarding its 
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reliability due to sampling error.28,29 Therefore, noninvasive methods to estimate liver 
fibrosis, like biomarkers and elastography, are also available and used widely today.  
Indirect biomarkers use a combination of laboratory tests, like platelets, aminotransferase 
(AST), and alanine aminotransferase (ALT), to estimate liver fibrosis. Two of the most 
commonly used to predict advanced fibrosis or cirrhosis include aspartate aminotransferase-
to-platelet ratio index (APRI) and FIB-4.28 Both use a patient’s AST and platelet count, but 
the FIB-4 also uses patient age and ALT levels.28 These indirect methods are better at 
confirming advanced liver disease but are less reliable at differentiating intermediate 
fibrosis.28 For example, in detecting moderate fibrosis (F2), the APRI had a sensitivity of 
84% and specificity of 41%. In diagnosing cirrhosis (F4), the sensitivity decreased to 54% 
but specificity increased to 78%.28 Therefore, it is suggested that providers use additional 
methods to predict liver fibrosis when using indirect markers of fibrosis. 
Finally, transient elastography offers a direct, noninvasive alternative to confirm liver fibrosis. 
It is an ultrasound-based method used specifically for the purpose of determining liver 
fibrosis. Transient elastography works by emitting a shear wave through the liver via an 
ultrasound transducer probe mounted on a vibrator.30 The velocity of the shear wave is used 
to determine the stage of liver fibrosis, measured in kilopascals.30,31 Compared to other 
noninvasive methods to measure liver fibrosis, transient elastography is one of the most 
accurate and reliable ways to estimate a METAVIR fibrosis score. For example, in 
diagnosing cirrhosis, transient elastography has a sensitivity and specificity of 95%, greatly 
surpassing that of other noninvasive methods. Specifically among a cohort of people who 
inject drugs, the cut-offs for significant fibrosis and cirrhosis were 9.3 and 12.3, respectively, 




HCV Transmission and Prevention 
HCV is transmitted primarily through percutaneous exposure to contaminated blood. 
Consistently, the most common mode of transmission has been shared injection drug use 
(IDU) practices.23,33,34 However, at its highest in 1982, non-A, non-B hepatitis transmission 
through blood transfusions accounted roughly 17% of all HCV cases, a percentage similar to 
those attributed to injection drug use.33 The percentage of transmission-related cases 
dropped to 6% in 1988, which was prior to the implementation of HCV antibody testing of 
blood donations, but did align with changes in the donation practices to decrease HIV 
transmission.33 Routine screening was implemented in 1990 and by 1994, counties that 
were part of the sentinel viral hepatitis surveillance system failed to identify a single case 
attributed transfusion-related transmission.23  
While transfusion-related transmission decreased, IDU-related transmission increased from 
roughly 20% in 1982 to 60% by 1998.23,33 It has likely increased even more, since the 
percentage of incident cases of acute HCV that report IDU as the primary risk exposure 
increased to 75% in 2011 and 82% in 2018.17,35 Per-event probability of transmission 
through shared drug use is estimated to be 0.57% but could be up to 6%, depending on 
prevalence of HCV in the injecting equipment.36 However, other sources of ongoing 
transmission remain, albeit contributing a far lesser extent to overall transmission. They 
include intranasal drug use, receiving a tattoo or piercing from unlicensed locations that 
reuses needles, nosocomial occupational exposures, being born to an HCV-positive mother, 
and through household contact, like sharing toothbrushes, razors, or diabetic needles.35   
Despite the lack of availability of a prophylactic vaccine, highly effective prevention 
measures are available. For example, primary prevention strategies used to reduce the risk 
of acquiring HCV initially included routine HCV screening of blood donations and expansion 
of syringe services programs to decrease the repeat usage of injection paraphernalia. 
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However, since the availability of direct acting antiviral (DAA) HCV treatment medications in 
late 2013, “treatment as prevention,” a concept borrowed from HIV, is also applicable to 
HCV. The goal of secondary and tertiary prevention methods has been to improve detection 
to reduce the risk of HCV-related morbidity and mortality. To do this, the CDC has expanded 
their testing recommendations. The initial 1998 CDC testing guidelines recommended 
screening of the highest-risk individuals, listed in Table 1.23 In 2012, the CDC updated the 
guidelines to include one-time testing among all individuals born between 1945 and 1965, 
as that age cohort comprised 75% of all HCV cases.37 Finally, in 2020, they were updated 
once again to recommend one-time testing on all individuals ≥18 years of age and pregnant 
women.34 Furthermore, as HCV treatment medications improved, the CDC also updated 
their testing algorithm in 2013 to facilitate better linkage to treatment.24 
*Adapted from the 1998 CDC Recommendations for Prevention and Control of Hepatitis C Virus 
Infection and HCV-Related Chronic Disease 
 
HCV Treatment Modalities 
HCV is a curable viral infection. The goal of HCV treatment is eradication of the infection 
(“cure”), which is defined as a sustained virologic response (SVR) indicating the absence of 
HCV RNA in serum at least 12 weeks after the end of treatment.5 There have been 
tremendous advances in HCV treatment, since it was first discovered that non-A, non-B 
Table 1. Criteria for HCV Antibody Testing Based on 1998 CDC HCV Testing 
Recommendations* 
History of injection drug use, even once or many years ago 
Received clotting factor concentrates produced before 1987 
Was placed on long-term hemodialysis 
Has persistent abnormal alanine aminotransferase levels 
If they were notified that they received blood from a donor who was later diagnosed with 
HCV 
Received a transfusion of blood or its components before July 1992 
Received an organ transplant before July 1992 
Nosocomial needlestick, sharps or mucosal exposure to HCV-positive blood 
Child born to an HCV-infected mother 
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hepatitis was curable in 1986. The history of HCV treatment modalities can be broadly 
organized into two eras, the interferon-era (1986-2013) and direct acting antiviral (DAA) era 
(2014-2020).  
Interferon Era of HCV Treatment 
Interferon (INF), found naturally in the human body, stops viral replication by both non-viral 
specific and viral specific immune responses that kill infected cells.38 The interferon-era of 
HCV treatment is known for long durations of complicated treatment regimens, drug-related 
adverse side effects, food restrictions, and poor overall cure rates. Additionally, not only did 
treatment outcomes vary by a variety of factors, including genotype, and evidence of 
cirrhosis, but there were numerous contraindications for treatment due to drug-drug 
interactions or side effects. 
The first FDA-approved treatment was interferon-alfa monotherapy administered using 
subcutaneous injections 3-times per week.38 Initially, treatment lasted for 6-months, with 6% 
of patients achieving SVR.5,38 Subsequently, treatment was extended to 12-months and 
SVR rates increased to 16%.5,38 Adding ribavirin was an early breakthrough that more than 
doubled cure rates, reaching 42%.5 In 2001, interferon-alfa was pegylated, which increased 
its half-life and decreased the number of weekly injections from three to one.5,38 However, 
SVR rates varied greatly by genotype, prior treatment experience, and evidence of 
cirrhosis.5,12,39 For example, SVR rates of genotypes 2 and 3 were as high as 80%, which 
was almost twice the SVR rates for genotype 1.5 Finally, with the FDA-approval of two 
protease inhibitors, boceprevir and telaprevir, in 2011, SVR rates exceeded 60% among 
some subgroups.38,39  
Adverse events were common in the interferon-era. In fact, roughly 75% of all patients who 
were on interferon-based therapy experienced at least one side effect.5 The most common 
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one was anemia since it was associated with all medications. But it was a major concern for 
those on ribavirin, as it was associated with severe anemia.5,38 Adverse events for 
interferon-alfa were also severe. They ranged from flu-like symptoms to depression and 
even life-threatening hepatic decompensation for those with cirrhosis.5,38 In fact, because of 
those side effects, treatment was contraindicated for those with uncontrolled depressive 
symptoms because it could increase the risk of suicide.5  
Interferon-based therapies also had high pill burden. For example, treatment guidelines from 
the American Association for the Study of Liver Diseases (AASLD) recommended that 
individuals with genotypes 1 and 4 receive weekly peginterferon injections plus ribavirin 
using weight-based dosing, which could be up to 6-pills daily, for 48 weeks.5,12,39 For 
genotypes 2 and 3, AASLD recommended weekly peginterferon injections with a lower fixed 
dosage of ribavirin for 24 weeks.5,12,39 The updated guidelines in 2011 added both telaprevir 
and boceprevir to treatment recommendations, which increased the number of pills taken 
daily by 6- or 8-pills, depending on the medication.39 Going into the DAA-era, treatment-
naive patients, without cirrhosis, weighing >165 pounds (75 kg) with genotype 1, the most 
common in the US, took 12 or 14 pills daily and received weekly injections of interferon for 
up to 48 weeks.39 
Direct Acting Antiviral Era of HCV Treatment 
Direct acting antivirals work by targeting nonstructural proteins involved in the HCV life 
cycle. The major classes are NS3/NS4A protease inhibitors, NS5A inhibitors, and NS5B 
polymerase inhibitors. The first two, simeprevir and sofosbuvir, were approved by the FDA in 
late 2013. However, sofosbuvir, specifically, was the breakthrough of DAA HCV treatment 
medications. It is a nucleotide analog inhibitor of NS5B polymerase that was approved by 
the FDA to be taken in combination with peginterferon-alfa and ribavirin to treat genotypes 
1-4.40,41 It is a single, well tolerated pill, taken once daily for between 12 and 24 weeks and 
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cure rates were >90%.40 Adverse events were attributed to the other medications but could 
include headache or fatigue.41 In November 2014, it was approved by the FDA to be used in 
combination with simeprevir to treat genotype 1, as the first all-oral, interferon-free HCV 
treatment regimen.42–44  
For the first 2-years of the DAA-era, HCV treatment regimen and response still varied by 
genotype and even subtype. For example, the 2015 AASLD HCV treatment guidelines 
recommended that patients with genotypes 1, 4, 5, or 6 take a single pill for 12 weeks.42 
Patients with genotypes 2 or 3 also took weight-based ribavirin and in some cases, 
interferon.42 A key game changer in HCV therapeutics was the approval of a pangenotypic 
fixed-dose pill, sofosbuvir-velpatasvir, which was FDA approved in 2016.45 Furthermore, 
SVR rates were >95%, regardless of liver fibrosis stage or prior HCV treatment 
experience.46,47 Since then, more pangenotypic medications have become available. In fact, 
today, treatment requires a single pill, taken daily for 8-12 weeks, with cure rates >98%.48 
Additionally, HCV treatment no longer requires food restrictions and there are minimal 
adverse events, drug-drug interactions, or contraindications for treatment.48 
When it was approved, sofosbuvir cost $1,000 per day or $84,000 for a 12-week course.49 In 
response, State Medicaid plans and Managed Care Organizations quickly implemented 
insurance restrictions that barred access to DAAs. Early restrictions included documentation 
of advanced liver fibrosis or cirrhosis, confirmation that the patient abstained from any drug 
use for up to 12 months, and requiring that only hepatologists, gastroenterologist, or 
infectious disease specialists could prescribe treatment. But these vary by state. For 
example, in 2014, 74% of the states required that patients have documentation of advanced 
liver fibrosis (METAVIR F3) or cirrhosis (METAVIR F4) to be approved for treatment.49 By 
2017, no states required a patient have cirrhosis but 23% still required documentation of 
advanced liver fibrosis.50 However, this decreased to 8% in 2019.51 Conversely the 
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percentage of states with no fibrosis restrictions rose from none, in 2014, to 35%, in 2017, 
and 79%, in 2019.49–51 Similar trends were seen with the sobriety restriction, which went 
from 100% requiring abstaining from substance use for up to 12 months to 36% requiring 
abstaining for substance use for up to 6 months.49,51 And today, only Arkansas requires that 
a specialist of prescribe HCV medications.51  
 
HCV Treatment among Key Populations  
HCV Treatment among Persons with HIV/HCV Coinfection 
A variety of factors influence the clinical course of HCV, but HIV/HCV coinfection is 
particularly important. Roughly 25% of all HIV-positive individuals in the United States are 
coinfected with HCV. However, among PWID, upwards of 90% of all HIV-positive PWID are 
coinfected with HCV.52 Coinfected individuals are at an increased risk of HCV-related 
mortality; a number of studies have demonstrated that progression to liver diseases, like 
cirrhosis, is accelerated by HIV.53 In fact, coinfection increases a person’s risk of cirrhosis 
two-fold.53,54 Today, HCV-related liver disease is one of the leading non-AIDS causes of 
death among people living with HIV.55,56 As a result, HCV treatment guidelines prioritized 
treatment among coinfected individuals.12,42 However, treatment of coinfected individuals in 
the interferon-era was complicated by toxicity concerns due to drug-drug interaction 
between antiretroviral and antiviral treatments, lower SVR rates among those who were 
treated, and exacerbated side effects, like ribavirin-related anemia.12,54 As a result, in the 
interferon-era, less than 5% of coinfected patients were treated.57,58 By comparison, today’s 
treatment regimens have shown no differences in SVR rates by HIV coinfection, no 
additional side effects, and fewer drug-drug interactions between antiretrovirals medications 
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and DAAs.59,60 As a result, treatment uptake has been better in HIV/HCV coinfected patients 
than HCV mono-infected.61  
HCV Treatment and Reinfection among Persons who Inject Drugs (PWID)  
Studies have already shown that treatment efficacy and SVR rates of both interferon-based 
and DAAs do not vary by drug use.62–65 However, some medical providers may still be 
reluctant to treat active PWID due to concerns of nonadherence and/or reinfection.66–69 In 
the interferon-era, studies failed to show significant differences in adherence to HCV 
treatment among PWID.65 For example, in one study, the overall rate of nonadherence was 
8.4% among those who used drugs, compared to 6.8% in those who did not.65 Moreover, 
studies in the DAA-era have shown excellent adherence to these shorter, simpler treatment 
regimens.62,70  
Even though HCV is curable, reinfection is possible. Studies in the DAA-era found that 
reinfection among people who have recently used drugs can range from none to over 20.0 
per 100 person-years.71–74 However, reinfection rates are lower among PWID who are 
engaged in harm reduction services.72,73 Despite the risk of reinfection, treatment guidelines 
consider PWID a high priority population. Similar to treatment as prevention (TasP) for HIV 
transmission, scaling up HCV treatment among PWID is an effective method to lower 
community load.75 This would, thereby, decrease HCV incidence and, by extension, 
prevalence, even if risk behaviors remain.76,77 
 
Epidemiology of HCV and Calls for HCV Elimination 
The hepatitis C virus (HCV) is the most prevalent bloodborne viral infection in the United 
States.23,37,78,79 Currently, it is estimated that 4.1 million people have been infected with 
HCV, of which 2.4 million have current HCV infection.79 At its peak, in the 1980s and early 
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1990s, the CDC estimated that there were, on average, 230,000 incident cases of acute 
HCV infection annually.23 These cases were primarily associated with shared risk behaviors 
among groups impacted by the nation’s cocaine and heroin epidemic in the 1980s and 
1990s.33 These cases were among Black individuals and persons between the ages of 30-
49 years.23 Most were unaware of their HCV infection and as these individuals aged, they 
began to experience the downstream effects of HCV that were associated with HCV-related 
morbidity and mortality.80 In fact, in 2007, HCV-related deaths exceeded those attributed to 
HIV.81 In 2013, they exceeded those attributed to the 60 other reportable infectious diseases 
combined, making it the leading cause of death due to an infectious disease in the United 
States.82 By the time that DAAs became available, HCV was the leading cause of end-stage 
liver disease, hepatocellular carcinoma and cirrhosis; as well as, the primary indicator for 
liver transplantation in the United States.40,83–85  
HCV incidence dropped sharply, starting in 1992 after the implementation of primary 
prevention measures for HCV and HIV and expanded awareness of HCV risk factors. 
However, starting in 2003 the number of reported cases of acute HCV infection stabilized 
until 2010, when HCV incidence began to increase again.86 In fact, the reported number of 
cases of acute HCV infections increased 4.1-fold between 2010 and 2018 to an estimated 
50,300 new infections in 2018.17,86 Similar to the 1980s and early 1990s, these cases are 
primarily among young individuals between the ages of 20-39 years.17 But they are also 
white, female, and live in suburban and rural areas of the United States, consistent with 
demographic groups impacted by the nation’s opioid epidemic.17,87–89 Because of the DAAs 
and the epidemiology of HCV, in 2015, the World Health Organization (WHO) and National 
Academies for Sciences, Engineering, and Medicine released two goals to eliminate HCV by 




Progress Towards HCV Elimination in the United States 
Progress has been made particularly on the mortality goal. The estimated number of people 
with chronic HCV infection decreased from 3.4 million in 2010 to 2.4 million in 2016.78,79 In 
fact, the overall age-adjusted HCV-related mortality rates peaked at 5 deaths/100,000 
population in 2014 and then decreased 26% to 3.7 deaths/100,000 population in 2018.17,20 
This was even more pronounced among those aged 55-64 years, the group with the highest 
mortality rate. At its highest in 2013, there were 25.2 deaths/100,000 population, which 
decreased to 17.3 deaths/100,000 population in 2018.17,20 Modelling done by the Polaris 
Observatory in 2020 confirmed this progress, estimating that the US would reach the HCV 
mortality goal by 2023, despite only successfully treating 40% of all HCV-infected individuals 
today.91  
By contrast, the Polaris Observatory found that the US is not on track to decrease HCV 
incidence by 90%.91 To achieve this goal, efforts must be made to improve HCV detection 
but also linkage to HCV treatment. The expansion of the CDC testing guidelines to perform 
universal testing on all over the age of 18 years, which augment routine testing already 
performed at services used by PWID, will improve the number of PWID who are aware of 
the diagnosis.34,92 However, this population faces a number of barriers to treatment. 
Reasons for poor HCV treatment uptake in the interferon-era were well characterized and 
included structural, provider, and individual-level barriers. The primary barrier to HCV 
treatment in the interferon-era was treatment itself, either low knowledge or fear of side 
effects.93–100 But medical providers were also reluctant to treat PWID due to stigma related 
to substance use, and concerns over non-adherence or reinfection.67,69,99,101,102 Additionally, 
non-specific barriers, like distrust of the healthcare system and insurance coverage, were 
also reasons why PWID chose to not receive HCV treatment.101,102  
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Since interferon-based treatments have been rendered obsolete, the primary barrier to HCV 
treatment has been removed. However, treatment uptake among PWID in the DAA-era 
remains low, overall. In fact, between 2015 and 2017, it was estimated that only 16% of 
PWID were treated with DAAs.77,103 It is clear that barriers remain. This proposal focuses on 
the identification of key barriers to HCV treatment uptake in the DAA era, including 
knowledge and other individual and structural barriers to engagement against a backdrop of 
a shifting epidemiology of drug use. 
 
HCV and PWID in Baltimore, Maryland 
With the highest number of PWID per capita in the country, Baltimore City has an 
established heroin epidemic that is exacerbated by prescription drug use and fentanyl.104 In 
2018, 89% of Maryland’s overdose deaths were opioid-related.105 In Baltimore City, the 
number overdose deaths increased 100% from 2015-2018.105 The effects of this widespread 
drug use are reflected in the city’s burden of HIV and HCV. Nationally, in 2016, <6% of HIV 
prevalence was attributed to IDU.106 Whereas, up to 30% of all HIV-positive residents of 
Baltimore reported IDU as the mode of transmission.107 HCV prevalence among PWID 
peaked at 93% in 1993 and remained high even as the overall incidence of acute HCV 
declined around the US.108,109 Finally, HCV treatment has increased markedly in Baltimore, 
but it is unclear if all groups are reached, notably PWID actively injecting or living outside of 
the city.110 
 
AIDS Linked to the Intravenous Experience (ALIVE) Study 
ALIVE is an ongoing prospective cohort of current and former PWID, ongoing since 1988.111 
Originally started to understand the natural history and incidence of HIV among PWID, 
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ALIVE is a seminal study that has helped to inform understanding of the epidemiology of 
HIV and HCV among PWID. The ALIVE study has contributed to our current understanding 
of the prevalence and incidence of HCV among PWID, uptake of HCV treatment and 
barriers to treatment in the interferon era. A 2008 study found that among ALIVE 
participants only 5% initiated HCV treatment and <1% were successfully cured.96 This was 
explained, in part, by low HCV knowledge and fear of treatment, consistent with other 
studies at the time.  
As a community-based cohort, participants are recruited independent of engagement in 
health or harm reduction services, through street outreach, flyer distribution, and peer 
referrals. ALIVE has maintained excellent follow-up rates, where 5% are lost-to follow-up 
and 2-3% die annually. As a result, ALIVE is comprised of individuals representative of the 
PWID community in Baltimore.  
Recruitment has spanned more than 3 decades and five cohorts: 1988-1989 (N=2,946), 
1994-1995 (N=434), 1997-1998 (N=295), 2005-2008 (N=1,009), and 2015-2018 (N=674). 
Eligible participants are ≥18 years of age with a history of IDU. In total, 5,358 individuals 
have been enrolled in ALIVE. For the first 20 years, participants have been older and non-
Hispanic Black.112 For example, in the original cohort, >92%% of the participants were Black 
and the median age was 51 years (IQR: 45 years, 54 years). But over the past 10 years, 
there was a shift in the demographics to include a younger and non-Hispanic white 
population. By comparison, in the most recent cohort 65% of the participants were Black 
and the median age dropped to 45 years (IQR: 33 years, 55 years). In fact, among non-
Hispanic white participants recruited in the 2015-2018 cohort, 50% were between the ages 
of 18-34 years. Over ALIVE’s 30-year study period, only a few participants were of Hispanic 
heritage. Prevalence of HCV and HIV/HCV coinfection has dropped slightly but remained 
high. In the 1988 cohort, roughly 85%-90% had HCV infection and 95% were coinfected with 
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HIV. In the most recent cohort, 70%-75% had HCV infection and 85% were coinfected with 
HIV. Finally, 15% of ALIVE participants live in counties surrounding Baltimore City. As a 
result, we have representation reflective of both a historical urban minority focused epidemic 
and an emerging epidemic that includes suburban areas and broader racial representation.  
At the baseline visit, ALIVE participants self-report demographic characteristics, drug use, 
and medical history. Participants are asked a series of questions to assess HIV and HCV 
knowledge, after which they are counseled regarding both diseases. At semi-annual visits, 
participants are asked about drug use, comorbidities, healthcare utilization, and report 
frequency of IDU within the past 30 days. Additionally, participants provide updated contact 
information, like residential address that is geocoded, and a FibroScan is performed to 
measure liver fibrosis.113 All questionnaires have been developed through focus groups with 
participants from the ALIVE community advisory board and collaborations with research on 
similar populations of PWID to those found in Baltimore. They are then pilot tested and 
modified based on the feedback from trained interviewers and participants. Participants are 
screened for HIV at each study visit using an enzyme-linked immunosorbent assay (ELISA) 
and Geenius HIV 1/2 Confirmatory Assay (Bio-Rad, Hercules, California). An HIV RNA test 
(Roche, Basel, Switzerland) is performed on HIV-positive participants at each visit to 
determine HIV viral suppression (≤50 copies/ml). All participants are screened for HCV 
antibodies using an ELISA (Ortho Clinical Diagnostics, Raritan, NJ) and confirm chronicity 
using an HCV RNA test (Abbott Molecular, Des Plaines, Ill). HCV RNA testing is conducted 
annually with additional testing to confirm cure among participants who self-report initiating 
HCV treatment between visits. Given the breadth of data, diversity of participants, location in 
Baltimore, and prior research in barriers to HCV treatment, ALIVE is an ideal in which to 





Our conceptual framework (Figure 1), adapted from Andersen’s behavioral model for 
healthcare utilization, hypothesizes that HCV treatment uptake among PWID is influenced 
by the contextual environment, as well as, a confluence of individual factors conceptualized 
as predisposing factors (demographics that change a person’s likelihood to access 
treatment), enabling resources (practical resources that impact ability to access treatment), 
and need (how perception of health motivates a person to access treatment).114,115 Our goal 
is to comprehensively assess how these different factors influence treatment uptake and 
what barriers persist among subgroups of PWID. Aim 1 will look at how treatment 
penetration in the community, varies across Baltimore neighborhoods where ALIVE 
participants reside and how neighborhoods with low treatment penetration vary by 
neighborhood characteristics and composition of individuals with respect to predisposing 
factors. In Aim 2, we will evaluate how a critical enabling resource “HCV knowledge” differs 
by predisposing factors and enabling resources. Finally, Aim 3 will look at changes in HCV 















Given the changes in the HCV treatment landscape, both modalities and accessibility, 
studies are needed to assess progress among PWID towards reaching the HCV incidence 
goal and identify groups that may not be accessing treatment today. The purpose of this 
thesis is to evaluate how treatment uptake among PWID has changed in Baltimore, 
Maryland. This compliments earlier work investigating barriers to HCV treatment during the 
interferon-era that was also conducted in the ALIVE study. The results can be used to 
inform programs and future research aimed at improving treatment uptake among PWID and 
support microelimination efforts in Baltimore, MD or other similar jurisdictions.   
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Background: With the continued increase in hepatitis C virus (HCV) incidence among people 
who inject drugs (PWID), studies are needed to understand potential barriers to HCV 
treatment. Geospatial analyses are a way to not only identify geographic areas of poor 
treatment uptake but also evaluate the extent to which characteristics of the neighborhoods 
or individuals explain the observed trends.  
Methods: Using serial cross-sectional data from the ALIVE study, which is a community-
based cohort of current and former PWID in Baltimore, MD, we performed a cluster 
detection analysis to identify hotspots of higher than expected rates of HCV viremia, which 
we used as an indicator for HCV treatment need. We did this over the following time-
periods, 2006-2007 (N=953), 2015-2016 (N=787), and 2017-2018 (N=528), meant to 
capture treatment penetration prior to direct acting antivirals, early in the availability of direct 
acting antivirals, and current assessment, respectively. Additionally, we performed a 
multilevel regression analysis to understand the environmental and individual-level factors 
that explained the clustering. 
Results: In the 2006-2007 time-period, the median proportion of viremic participants in 
Census tracts was 83%. We identified a single cluster, located in Central Baltimore City, that 
was in areas where the prevalence of HCV viremia was >91% and in areas of highest 
neighborhood deprivation (aOR: 6.55, 95% CI: 4.27, 10.05). The median proportion of 
viremic participants per Census tract decreased to 64% in the 2015-2016 time-period. 
Additionally, we identified two clusters in East and West Baltimore City. The odds of being in 
either of the clusters were higher among participants who are Black (aOR: 2.53, 95% CI: 
1.41, 4.56) and increased with neighborhood deprivation. In the 2017-2018 time-period, the 
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median proportion of viremic participants per Census tract was 39% and we failed to identify 
any clusters of poor treatment penetration.  
Conclusion: We found that HCV treatment penetration improved throughout Baltimore City 
and Baltimore County between the interferon and direct acting antiviral (DAA) eras. While it 
appears that by the late DAA-era (2017-2018) that treatment had penetrated all parts of 




Hepatitis C virus (HCV) is the most common bloodborne infection in the US, with 2.4 million 
people chronically infected.1 Injection drug use (IDU) continues to be the most common risk 
factor, and HCV prevalence among people who inject drugs (PWID) ranges between 50%-
90%.2–5 In the US, the reported number of cases of acute HCV infection was decreasing in 
1992 and stabilized around 2004. However, between 2010 and 2018 the reported number of 
cases increased 4.1-fold.6–8 This increase was driven primarily by high incidence among 
young PWID who were increasingly white, female and living outside of urban settings, 
consistent with the shifting epidemiology of injection drug use across the US.9–11 By contrast, 
HCV-related mortality is highest among individuals born between 1945-1965, who were 
infected in the 1990s, when HCV incidence peaked in the US.7,12  
Of those infected with HCV, roughly 25% will spontaneously clear the virus.13 Therefore, 
confirmatory HCV RNA testing is required to determine HCV chronicity. The 75% who do not 
spontaneously clear the virus will have a detectable HCV RNA viral load, indicating chronic 
HCV infection and a need for HCV treatment. Prior to 2013, HCV treatment lasted up to 48 
weeks, included weekly interferon injections, adverse side effects, and cure rates of 
<50%.13–15 Today, treatment requires one pill taken daily for as few as 8-weeks, and cure 
rates of >95%.16–20 Because of the high burden of HCV, the increasing occurrence of liver-
related morbidity and mortality secondary to HCV and advancements in treatment, in 2015, 
the World Health Organization and National Academies of Science, Engineering, and 
Medicine have set a goal to eliminate HCV by 2030 by specifically, lowering HCV incidence 
by 90% and HCV-related mortality by 65%.21,22  
To meet these goals, countries around the world have made efforts to increase both HCV 
screening and linkage to treatment. However, limited progress has been made. Modelling 
done by the Polaris Observatory found that of 45 high-income countries, only nine were on 
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track to eliminate HCV by 2030 and an additional six by 2050.23 While the United States is 
projected to achieve the HCV-mortality goal of 65% reduction by 2023, it is not on track to 
meet the HCV incidence goal.23 In particular, in order to reduce HCV incidence, efforts will 
need to focus on treating all infected persons with hepatitis C particularly those groups that 
are driving ongoing transmission, such as PWID. But resources are limited and PWID 
experience a combination of individual, provider and structural barriers to HCV treatment.24–
27 In fact, it is estimated that only 16% of PWID were treated with DAAs between 2015 and 
2017.28,29 
To address this discrepancy, innovative strategies to identify and engage PWID in HCV 
treatment are needed. Use of geographic information system (GIS) and spatial statistical 
methods have been widely used to improve screening programs, allocate resources, and 
even identify key populations at risk.30–33 In particular, cluster detection can be used to 
identify areas where the observed rates of disease are higher than what would be expected. 
Indeed, research using cluster detection approaches has helped to identify and characterize 
hotspots of HCV infection and HCV-related morbidity and mortality.27,34,35 Similarly, this type 
of analysis can be used to identify areas with lower than expected penetration of HCV 
treatment. Further understanding of individual and structural factors that differentiate the 
observed clusters of infection and/or low treatment penetration and how these change over 
time can be used to better understand gaps in service delivery and highlight where to target 
resources or interventions.   
The aim of this paper is to examine changes in the spatial distribution and clusters of HCV 
treatment need among PWID in Baltimore City and Baltimore County, Maryland, over three 
time-periods: 2006-2007 (pre-DAA era), 2015-2016 (early years of DAA availability), and 
2017-2018 (later years of DAA availability). Furthermore, we examined whether any 





The AIDS Linked to the IntraVenous Experience (ALIVE) study is a community-based cohort 
of current and former PWID that has been described elsewhere.36 In total, 5,358 individuals 
have been enrolled in ALIVE over five time periods: 1988-1989 (N=2,946), 1994-1995 
(N=434), 1997-1998 (N=295), 2005-2008 (N=1,009), and 2015-2018 (N=674). All 
participants are ≥18 years of age and had a history of injection drug use (IDU) at enrollment. 
For the purposes of this analysis, we included all HCV-antibody positive participants who 
reported living in either Baltimore City or Baltimore County and received confirmatory HCV 
RNA testing. Additionally, each included participant had at least one clinic visit in one of 
three time periods: 2006-2007 (N=953), 2015-2016 (N=787), and 2017-2018 (N=528). A 
positive HCV RNA test indicated the participant had chronic HCV infection and was eligible 
for treatment; whereas a negative HCV RNA test was defined as either spontaneous 
clearance or successful treatment in the past. The time periods were selected to examine 
the period prior to the availability of direct acting antivirals (2006-2007), early in the 
availability of direct acting antivirals when multiple restrictions reduced access to HCV 
treatment (2015-2016), and a current assessment of HCV treatment need, 4-years since the 
availability of direct acting antiviral agents (2017-2018).13,37–40  
Data Measurement 
At baseline, participants provided information regarding sociodemographic characteristics 
(i.e. age, sex, race, education level). At semi-annual visits, participants were asked whether 
they were incarcerated for at least 7-days, recent drug use, used syringe service program, 
and health-related variables (i.e. type of insurance, whether a participant has a primary care 
provider, and whether a participant had an outpatient or emergency department visit) 
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through standardized questionnaires that were administered by either a trained interviewer 
or audio computer-assisted self-interview (ACASI). Variables collected at the semi-annual 
visits reflect usage in previous 6-months. All participants were screened for HCV antibodies 
at their baseline visit using an enzyme-linked immunosorbent assay (ELISA) (Ortho Clinical 
Diagnostics, Raritan, NJ) and received confirmatory testing using an HCV RNA test (Abbott 
Molecular, Des Plaines, Ill). HCV RNA testing was conducted annually with additional testing 
to confirm cure among participants who self-reported initiating HCV treatment between 
visits. Participants were screened for HIV at each study visit using an ELISA and Geenius 
HIV 1/2 Confirmatory Assay (Bio-Rad, Hercules, California). An HIV RNA test was 
performed on HIV-positive participants at each visit to determine HIV viral suppression (≤50 
copies/ml). A FibroScan, which is an ultrasound that measures liver stiffness (i.e. fibrosis), 
was also performed. At each visit, participants provided an updated residential address that 
was geocoded and mapped using ArcGIS 10.7 (ESRI, Redlands, California) to 2010 US 
Census tracts. For participants with more than one visit in a study period, we included the 
address and responses reported at the first visit.  
For the analysis, we evaluated individual-level variables that had been previously associated 
with treatment uptake, including demographics (i.e. age, sex, race, education level), whether 
a participant was incarcerated for at least 7-days, HIV status and HIV viral load, type of 
health insurance, recent engagement in medical care (i.e. having regular source of primary 
care, outpatient visit, visit to emergency department), use of harm reduction services (i.e. 
visit to syringe service programs) and type of drug use.37,41–43 All variables, except 
demographic characteristics reflect use in the previous 6-months. We categorized type of 
drug use, based on if the participant reported no recent drug use, injection drug use only 
(i.e. injection of heroin, methamphetamine, cocaine, or speedball), non-injection drug use 
only (i.e. smoking crack or heroin), or both injection and non-injection drug use. 
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In addition to individual level characteristics, we examined neighborhood-level factors 
impacted treatment need. Specifically, we evaluated neighborhood deprivation, as it has 
been previously associated with increased treatment need in other studies.34,44 To measure 
neighborhood deprivation, we created a neighborhood deprivation score for the 200 Census 
tracts that make up Baltimore City and 214 that make up Baltimore County using variables 
obtained from the 2011-2015, 5-year estimate from the American Community Survey .45 
Scores were calculated from a scale that was created using a principle component analysis 
with the following seven indicators that had been validated in Baltimore, Maryland and used 
in prior studies among ALIVE participants: percent of individuals in professional/managerial 
occupations, percent of households receiving public assistance, percent of households with 
crowding, percent of households living below the federal poverty level, percent female 
headed households living with dependent children (<18 years of age), percent of individuals 
with high school education or less, and percent of males and females (>16 years) that were 
unemployed.45–47 The principle component analysis was performed on all 414 Census tracts, 
but our analysis only includes those with at least one ALIVE participant. In total, there were 
209 Census tracts included for the 2006-2007 time-period, of which 157 (75.1%) were in 
Baltimore City, 211 Census tracts included for the 2015-2016 time-period, of which 162 
(76.8%) were in Baltimore City, and 179 Census tracts included for the 2017-2018 time-
period, of which 147 (82.1%) were in Baltimore City.  
Statistical Analysis 
We first compared the sociodemographic and behavioral characteristics of participants who 
were HCV RNA positive (indicating treatment need) and those who were HCV RNA negative 
using a chi-squared or Fisher’s exact test for categorical variables, and a Wilcoxon-Mann-
Whitney test for continuous variables. Because the proportions in Census tracts with a small 
number of ALIVE participants can be unstable or extreme, we mapped the spatial 
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distribution of HCV treatment need pre- and post-availability of DAAs by using Empirical 
Bayes Smoothing to calculate the smoothed proportion of ALIVE participants with chronic 
HCV infection throughout Baltimore City and Baltimore County using GeoDa 1.14.0.48,49 This 
technique uses study data to estimate parameters, which are a weighted average of the raw 
data and a global average. The magnitude of the weight is proportionate to the population 
at-risk.50 As such, proportions from Census tracts with a small number of ALIVE participants 
will be weighted more than Census tracts with larger numbers of ALIVE participants.49 The 
results were exported from GeoDa and visualized using ArcGIS for the three time periods 
(2006-2007, 2015-2016, and 2017-2018). Results ranged from 0, indicating none, and 1, 
indicating all ALIVE participants in that Census tract required HCV treatment.  
We identified statistically significant clusters of greater than expected treatment need based 
on the ratio of ALIVE participants with chronic HCV infection in each potential cluster using 
SaTScan Version 9.4.4, a cluster detection software.51 SaTScan uses a circular moving 
window method to compare the number of observations in the study data with the expected 
number observations, determined using indirect standardization, within each potential 
candidate cluster. The potential clusters are evaluated using a likelihood ratio test, which are 
compared to 999 simulated likelihood ratios using Monte Carlo simulations. Finally, a p-
value is assigned to identify the most likely clusters, removing those that were likely to 
appear due to chance.51,52 The maximum cluster size was set to 25% of the population at-
risk and required at least 4 cases to be considered a cluster. Clusters presented in the 
results had a p-value<0.05.  
Initially, we performed a purely spatial cluster detection that used a Bernoulli model, where 
individual participant locations are treated as cases (i.e. those who were HCV RNA positive), 
or controls (i.e. those who were HCV RNA negative), and used a maximum likelihood ratio 
test to identify scanning windows with an elevated likelihood of HCV viremia. For each 
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potential cluster, the null hypothesis is complete spatial randomness of cases and controls, 
where the ratio of participants with a detectable HCV RNA test in the potential cluster is 
equal to the ratio outside of the cluster. Additionally, we restricted the analysis to include all 
data from 2015 through 2018 to perform a Bernoulli space-time cluster detection (since 
annual data were only available from this time-period). This approach is like the purely 
spatial scan statistic, except data are treated longitudinally. This allows for the identification 
of clusters over different durations of time. In a space-time scan statistic, a cylinder, rather 
than circular window, is used to identify clusters. The height is based on the duration that 
the cluster is present. Results from both scan statistics were imported into ArcGIS to 
visualize the detected clusters.     
A subsequent analysis adjusted for participant characteristics and neighborhood deprivation 
of each Census tract to examine the degree to which clusters were explained by individual 
and neighborhood-level factors. The same variables were included for the three time periods 
for comparability and chosen based on a priori knowledge, as they had been shown to be 
independently associated with HCV treatment uptake in other studies. Multilevel logistic 
regression was performed using Stata 14 (StataCorp, College Station, Texas) to calculate 
the predicted probability of a participant having chronic HCV infection. Since the predicted 
probabilities are treated as a continuous variable, they were analyzed using the Gaussian 
(i.e. normal) model when imported back into SaTScan. This adjusted analysis identified 
clusters that were not explained by the regression covariates. The process was repeated for 
each of the three time-points to evaluate how clusters of poor treatment uptake changed 
over time.  
Finally, we used multilevel logistic regression to identify factors independently associated 
with the clusters of HCV treatment need. Specifically, we compared persons who reported 
residence inside vs. outside an identified significant cluster as the dependent variable in a 
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model. For continuity, variables included in the final model were the same as those used in 
the adjusted cluster detection. This analysis was also performed using Stata 14 (StataCorp, 




Baseline characteristics of the study participants are presented in Table 1. Among the 953 
HCV-antibody positive participants in the 2006-2007 time period, 798 (84%) had chronic 
HCV infection, the median age was 48 years, 68% were male, 85% were Black, 26% were 
insured through Medical Assistance, and 56% reported injecting drugs in the previous 6-
months. In 2015-2016, 64% of the 787 participants had chronic HCV infection, the median 
age was 56 years, percentage that were male was 78%, 88% were Black, 53% had Medical 
Assistance, and 27% reported recent injection drug use. Finally, prevalence of chronic HCV 
was 57% among the 528 HCV-antibody positive participants with a visit in the 2017-2018 
time period, the median age was 57 years, 67% were male, 91% were Black, 48% had 
Medicaid Assistance, and 32% injected drugs in the last 6 months.  
Spatial Analysis Results 
Figure 1 shows that the proportion of HCV-antibody positive participants requiring HCV 
treatment per Census tract decreased over the three study periods. The median percentage 
of participants with HCV viremia in Baltimore City and Baltimore County fell from 83% in the 
interferon-era, to 64% in the early DAA-era, and finally 39% in the later DAA-era. In 
Baltimore City, the percentage of Census tracts in which ≥74% of the participants had HCV 
viremia dropped from 89% in the interferon-era to 20% in the early DAA-era and 2% in the 
later DAA-era.   
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Purely Spatial Cluster Detection 
Results from the purely spatial cluster detection identified a single cluster of higher than 
expected HCV treatment need located in Central Baltimore City in the interferon-era (Figure 
2a). The cluster was located in an area where the proportion of HCV viremic ALIVE 
participants exceeded 0.91. No clusters were identified using a purely spatial cluster 
detection for the two later time-periods. We performed an adjusted cluster detection using a 
normal model for all three time-periods but failed to identify any significant clusters (p>0.05). 
Participant and neighborhood-level characteristics of the identified clusters in the interferon-
era (2006-2007) are presented in Table 2. While being Black was associated with a 68% 
(95% CI: 1.02, 2.74) increase in the odds of being in a cluster in the univariable analysis for 
the 2006-2007 time-period, it failed to retain statistical significance after adjusting for other 
sociodemographic characteristics, healthcare utilization, recent drug use, and neighborhood 
socioeconomic status. Neighborhood deprivation was significantly associated with being in a 
cluster in univariable and multivariable analysis. Clusters had more than 6 times the odds 
(95% CI: 4.09, 9.93) of being in a highly deprived Census tract compared to not being in a 
cluster in the adjusted model.  
Space-Time Cluster Detection 
We identified two clusters in the early DAA-era (2015-2016) using the space-time cluster 
detection for 2015-2018 (Figure 2b). The location of the clusters coincides with where the 
proportion of HCV-antibody positive participants with detectable HCV viremia was highest in 
East and West Baltimore City. Subsequently, we performed an adjusted cluster detection 
using a normal model. We failed to identify any significant clusters (p>0.05) after controlling 
for sociodemographic characteristics, recent drug use, and healthcare utilization. The 
participant and neighborhood-level characteristics describing the two identified clusters in 
the early DAA-era are presented in Table 2. The odds of being in a cluster were higher if a 
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participant was older (OR: 1.02; 95% CI: 1.00, 1.04), if a participant was Black (OR: 3.01; 
95% CI: 1.78, 5.10), , and in the most deprived Census tracts. In the adjusted model, all 
levels of neighborhood deprivation and Black race (aOR: 2.53; 95% CI: 1.41, 4.56) 
continued to be significantly associated with higher odds of being in a cluster, although the 
associations were attenuated. 
 
DISCUSSION 
Our study found that there was significant penetration of HCV treatment in Baltimore City 
and Baltimore County. There was a 23% decrease in the median proportion of viremic 
participants between the interferon-era and the early DAA-era and a 39% decrease between 
the early and later DAA time-periods. Results from the cluster detection analysis identified 
clusters in both the pre-DAA and early DAA eras, which reflect, in part, where infections 
were located, as well as areas where access or prioritization of healthcare may have been 
impeded by poverty. It was encouraging that we did not identify clusters in the later DAA-
era, which could indicate that HCV treatment among PWID has penetrated throughout 
Baltimore and may even be reaching the most vulnerable.     
Clusters of poor treatment uptake that were identified in the interferon-era and early in the 
DAA-era, highlight health inequities resulting from poverty. In the interferon-era, many 
providers and patients chose to defer treatment until DAAs became available.53,54 Since 
treatment uptake was so low, the cluster of HCV viremia likely represented where HCV 
infection was located. Starting in 2014, treatment uptake improved initially. However, the two 
early DAA-era clusters detected in East and West Baltimore City show that it was not 
uniform across the city. While we did not identify many factors that differentiated clusters of 
elevated HCV treatment need, in both periods, neighborhood deprivation and race was 
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associated with a significantly higher likelihood of being in a cluster. In both the interferon 
and early DAA-era, HCV treatment initiation has been shown to differ by race, with Black 
individuals being less likely to start HCV treatment than their white counterparts.55–57 So it 
was not surprising that Black race was associated with being in a cluster of HCV treatment 
need. Moreover, poverty is known to be associated with negative health outcomes, often 
due to poor healthcare accessibility. The identified clusters were located in Central, East 
and West Baltimore, which are areas with high levels of neighborhood deprivation, but they 
are also home to major health systems where PWID can receive HCV treatment. Further 
research is needed to elucidate if the treatment delay was related to poor access to HCV 
care or provider and individual-level barriers affecting treatment initiation, like stigma or 
competing priorities.  
Remarkably, in failing to identify any clusters in the later DAA time-period, we found that 
HCV treatment had penetrated the PWID community, and in a more equitable manner. It is 
likely a result of a mixture of factors that occurred over the 4-years since DAAs became 
available. For example, efforts were made to expand HCV treatment into primary care, 
which increased the number of providers that treat HCV, and awareness of DAAs improved 
the longer they were available.58 Additionally, changes in Maryland’s Medicaid restrictions 
may also explain why treatment uptake among ALIVE participants continued to improve 
throughout the DAA-era. Early in their implementation, participants able to circumvent the 
restrictions were older, had cirrhosis, and had not injected drugs in some time. However, we 
found that the percentage of chronically infected participants with cirrhosis and who had no 
recent drug use decreased between the early and late DAA-eras, despite the percentage of 
participants with Medicaid staying roughly the same.58 This is encouraging, as it shows that 




Even though treatment uptake improved over the study period, 43% of those with visits in 
the late DAA-era were in need of treatment. These groups may be the most challenging to 
reach, suggesting that increased efforts will be needed to ensure these PWID initiate 
treatment. Our results showed that the median percentage of viremic participants fell to 39% 
in the late DAA-era, but was over 63% in areas in East and West Baltimore and 91% in 
Southwest Baltimore, MD. Further research is needed to understand the individual barriers 
these PWID are experiencing. But public health officials could use our results to place 
support that is aimed to improve access to treatment in these locations.  
Our study is not without limitations. First, we did not include whether a person self-reported 
treatment at a visit and so, the presence/absence of viremia reflects a combination of 
treatment and spontaneous clearance. Results from the interferon-era most likely reflect 
spontaneous clearance of HCV since so few participants were treated. The mere reduction 
in HCV viremia in the latter two time periods reflects at least some contribution of treatment; 
in the absence of treatment uptake, that proportion would be expected to remain stable.53 
While ALIVE is a longitudinal cohort, the analyses looked at serial cross-sections given that 
HCV viremia data were not available for every participant at every visit. While HCV and HIV 
status were laboratory confirmed in our study, other variables, like drug use and healthcare 
utilization, are based on self-report and are subject to recall bias. An earlier study in ALIVE 
evaluated social desirability responding in discussing recent drug use and found high 
reliability and validity.59,60 Finally, since participants volunteer to be in the ALIVE study, 
participants may not be representative of the larger population of PWID in Baltimore or in 
other geographic areas. However, the demographic characteristics between cohorts suggest 
that the ALIVE study remains representative of the underlying population of PWID. 
To decrease HCV incidence by 90%, efforts must be made to improve treatment uptake 
among PWID. Geospatial analyses could help inform interventions aimed to identify areas 
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which would benefit most from additional resources to improve linkage to treatment and 
monitor the effect overtime. Our study successfully used geospatial and statistical analysis 
to identify and explain changes in areas of poor HCV treatment penetration among ALIVE 
participants living in Baltimore City and Baltimore County in three time periods. Results can 
be used by public health officials to continue to monitor HCV treatment need and intervene 
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Table 1. Individual and neighborhood characteristics of HCV-antibody ALIVE participants by HCV RNA status, Baltimore City and Baltimore County, 2006-2018 

















N 155 798   286 501   302 226   
Demographic Characteristics                   
Age (years), mean (IQR) 45.3 (8.5) 47.7 (8.0) <0.01 57.3 (7.8) 55.1 (8.1) <0.01 57.5 (6.9) 54.6 (8.0) <0.01 
Black race 119 (76.8%) 695 (87.1%) <0.01 250 (87.4%) 443 (88.4%) 0.67 279 (92.4%) 201 (88.9%) 0.17 
Female sex 70 (45.2%) 235 (29.4%) <0.01 97 (33.9%) 156 (31.1%) 0.42 100 (33.1%) 75 (33.2%) 0.99 
≥High school diploma 65 (41.9%) 313 (39.3%) 0.54 130 (45.5%) 199 (39.9%) 0.13 136 (45.0%) 92 (40.9%) 0.34 
Incarcerated for at least 7 days 23 (14.8%) 141 (17.9%) 0.36 9 (3.2%) 18 (3.6%) 0.75 5 (1.7%) 9 (4.0%) 0.10 
Comorbidities and Healthcare Utilization                
Estimate of fibrosis (liver scarring)                
   Mild liver scarring 59 (38.1%) 190 (23.9%) 
<0.01 
78 (27.4%) 128 (25.6%) 
<0.01 
78 (25.9%) 44 (19.5%) 
0.02 
   Significant liver scarring 8 (5.2%) 98 (12.3%) 23 (8.1%) 62 (12.4%) 40 (13.3%) 52 (23.0%) 
   Severe scarring 5 (3.2%) 46 (5.8%) 9 (3.2%) 40 (8.0%) 27 (9.0%) 21 (9.3%) 
   Cirrhosis 83 (53.5%) 462 (58.0%) 175 (61.4%) 270 (54.0%) 156 (51.8%) 109 (48.2%) 
HIV status and HIV viral suppression1 38 (24.5%) 234 (29.3%)  116 (40.6%) 163 (32.5%)  183 (60.6%) 100 (44.2%)  
   HIV negative 117 (75.5%) 564 (70.7%) 
0.19 
170 (59.4%) 338 (67.5%) 
<0.01 
119 (39.4%) 126 (55.8%) 
<0.01    HIV-positive with undetectable viral load 10 (6.5%) 90 (11.3%) 109 (38.1%) 110 (22.0%) 144 (47.7%) 55 (24.3%) 
   HIV-positive with detectable viral load 28 (18.1%) 144 (18.1%) 7 (2.5%) 53 (10.6%) 39 (12.9%) 45 (19.9%) 
Insurance status2                
   No insurance 70 (45.2%) 331 (41.6%) 
0.83 
8 (2.8%) 10 (2.0%) 
0.03 
5 (1.7%) 2 (0.9%) 
<0.01    Insurance through Medical Assistance 40 (25.8%) 213 (26.8%) 133 (46.5%) 282 (56.5%) 122 (40.5%) 131 (58.5%) 
   Other type of insurance 45 (29.0%) 251 (31.6%) 145 (50.7%) 207 (41.5%) 174 (57.8%) 91 (40.6%) 
Had a primary care provider2 109 (70.3%) 573 (71.8%) 0.71 264 (92.3%) 445 (88.8%) 0.12 285 (94.4%) 197 (87.2%) <0.01 
Had outpatient visit2 80 (51.6%) 423 (53.0%) 0.75 242 (84.6%) 371 (74.1%) <0.01 267 (88.4%) 167 (73.9%) <0.01 
Visited emergency department2 44 (28.4%) 255 (32.0%) 0.38 86 (30.1%) 150 (29.9%) 0.97 77 (25.7%) 78 (34.7%) 0.03 
Drug Use Practices                
Type of drug use2                
   None 52 (33.5%) 294 (36.9%) 
0.56 
202 (70.6%) 273 (54.7%) 
<0.01 
183 (60.6%) 93 (41.3%) 
<0.01    Injection drug use only 30 (19.4%) 170 (21.3%) 21 (7.3%) 61 (12.2%) 29 (9.6%) 34 (15.1%) 
   Non-injection drug use only4 16 (10.3%) 61 (7.7%) 29 (10.1%) 72 (14.4%) 41 (13.6%) 40 (17.8%) 
   Both 57 (36.8%) 272 (34.1%) 34 (11.9%) 93 (18.6%)  49 (16.2%) 58 (25.8%)  
Visited the syringe service program2 25 (16.2%) 110 (13.8%) 0.43 22 (7.7%) 73 (14.6%) <0.01 29 (9.6%) 51 (22.7%) <0.01 
Neighborhood Characteristics                
Neighborhood deprivation score                
   Quartile 1 (lowest level of deprivation) 41 (26.5%) 203 (25.4%) 
0.26 
88 (30.8%) 112 (22.4%) 
<0.01 
78 (25.8%) 54 (23.9%) 
0.36 
   Quartile 2 34 (21.9%) 205 (25.7%)  61 (21.3%)  134 (26.7%) 83 (27.5%) 52 (23.0%) 
   Quartile 3 49 (31.6%) 198 (24.8%) 58 (20.3%) 142 (28.3%) 68 (22.5%) 65 (28.8%) 
   Quartile 4 (highest level of deprivation) 31 (20.0%) 192 (24.1%) 79 (27.6%) 113 (22.6%)  73 (24.2%) 55 (24.3%) 
1Viral suppression is defined as ≤50 copies per mL 
2Reflective of last 6 months 
3Includes injection of heroin, cocaine, speedball (heroin and cocaine together), methamphetamine or any other type of drug 




Table 2. Participant and neighborhood-level correlates of membership in a cluster of elevated HCV treatment need among ALIVE participants, Baltimore City and Baltimore 
County, 2006-2007 and 2015-2016 
  Characteristics of 2006-2007 unadjusted purely spatial cluster Characteristics of 2015-2016 unadjusted space-time clusters 
  OR (95% Conf. Interval) aOR (95% Conf. Interval) OR (95% Conf. Interval) aOR (95% Conf. Interval) 
Age (years) 1.01 (0.99, 1.03) 1.00 (0.97, 1.02) 1.02 (1.00, 1.04) 1.00 (0.98, 1.03) 
Participant's race     
   Non-Black REF REF REF REF 
   Black 1.68 (1.02, 2.74) 1.24 (0.67, 2.28) 3.01 (1.78, 5.10) 2.53 (1.41, 4.56) 
Participant's sex     
   Male REF REF REF REF 
   Female 1.13 (0.82, 1.57) 1.00 (0.67, 1.49) 1.29 (0.95, 1.74) 1.20 (0.87, 1.67) 
HIV status and HIV viral suppression1     
   HIV negative REF REF REF REF 
   HIV-positive with undetectable viral load 0.90 (0.53, 1.52) 0.94 (0.51, 1.73) 1.11 (0.80, 1.53) 1.09 (0.77, 1.54) 
   HIV-positive with detectable viral load 1.09 (0.73, 1.62) 1.23 (0.77, 1.96) 1.17 (0.68, 2.01) 1.04 (0.59, 1.83) 
Had outpatient visit2     
   No  REF REF REF REF 
   Yes 0.83 (0.61, 1.12) 0.82 (0.57, 1.18) 1.15 (0.81, 1.63) 1.11 (0.76, 1.61) 
Type of drug use2     
   None REF REF REF REF 
   Injection drug use only3 1.01 (0.66, 1.55) 0.90 (0.54, 1.49) 1.19 (0.74, 1.92) 1.32 (0.80, 2.18) 
   Non-injection drug use only4 1.25 (0.70, 2.23) 0.90 (0.46, 1.75) 1.23 (0.80, 1.89) 1.29 (0.82, 2.03) 
   Both 1.12 (0.78, 1.62) 1.03 (0.66, 1.60) 0.96 (0.64, 1.43) 1.03 (0.67, 1.58) 
Neighborhood deprivation score     
   Quartile 1 (lowest level of deprivation) REF REF REF REF 
   Quartile 2 0.55 (0.32, 0.95) 0.53 (0.31, 0.92) 2.66 (1.72, 4.12) 2.53 (1.63, 3.94) 
   Quartile 3 0.34 (0.19, 0.63) 0.34 (0.18, 0.62) 3.31 (2.15, 5.10) 3.01 (1.93, 4.69) 
   Quartile 4 (highest level of deprivation) 6.55 (4.27, 10.05) 6.37 (4.09, 9.93) 3.10 (2.01, 4.80) 2.89 (1.85, 4.52) 
1Viral suppression is defined as ≤50 copies per mL 
2Reflective of last 6 months 
3Includes injection of heroin, cocaine, speedball (heroin and cocaine together), methamphetamine or any other type of drug 





























Purely Spatial Cluster, 2006-20017 105 91 9.56 1.15 0.03 
Space-Time Cluster 1, 2015-2016 68 46 13.04 1.51 <0.01 






Figure 1. Spatial distribution of HCV treatment need by Census tract among ALIVE participants using Empirical Bayes Smoothing, 

































*The background choropleth map are the smoothed results from Figure 1.  
Note: No statistically significant clusters were identified in the last time-period, 2017-2018 or in the adjusted analyses.
Figure 2a. Unadjusted purely spatial cluster of HCV treatment need in Baltimore City and Baltimore County, 2006-2007* 
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Background: Two commonly cited barriers to interferon-based treatment were low knowledge of 
HCV and fear of treatment-related side effects. With the availability of direct acting antivirals 
(DAA), interferon-based therapies are now obsolete, but treatment uptake remains low in 
subgroups of people who inject drugs (PWID). It is possible that knowledge of DAAs may 
motivate some to seek treatment but, the extent to which information about DAAs has 
penetrated PWID is not well-characterized.  
Methods: Using results from a 17-item assessment of HCV knowledge, collected from 826 
current and former PWID who were recruited into the ALIVE study between 2015-2018, we 
created three knowledge scores to measure awareness of HCV-related transmission (7-
questions), HCV natural history (5-questions), and HCV treatment (3-questions) by HIV and 
HCV status. We used the highest quartile of responses as the cut-point for high/low knowledge 
on the transmission and natural history subscales. A participant was classified as having high 
treatment knowledge if they correctly answered the 3 treatment-related questions. 
Subsequently, we performed a logistic regression to identify subgroups of PWID who were at-
risk of low HCV knowledge.  
Results:  Nearly all participants correctly answered which injection drug use related practices 
could result in HCV transmission and that HCV negatively affects a person’s liver (95%) but is 
largely asymptomatic (97%). While 80% correctly answered that HCV was curable, only two-
thirds correctly stated that HCV treatment now has fewer side effects, shorter duration, and 
decreased pill burden, compared to interferon-based therapies. Overall, 23% of the participants 
had a high transmission knowledge score and no independent predictors of having high 
transmission knowledge were identified. In the natural history subscale, 31% of the participants 
had a high knowledge score and high knowledge was associated with having a high school 
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diploma (aOR: 1.41, 95% CI: 1.02, 1.95), and having shared needles in the past. In total, 78% of 
the participants had high knowledge of HCV treatment. We found that high treatment knowledge 
was associated with being HCV mono-infected compared to HCV negative. Additionally, among 
those who were HCV positive, treatment knowledge was higher among those diagnosed with 
HCV prior to study entry, compared to those who were diagnosed through HCV testing at 
ALIVE.  
Conclusion: HCV knowledge among this population of PWID was high. However, misinformation 
about interferon-based therapies remain. Treatment knowledge was lowest among participants 
who were HCV negative or unaware of their HCV infection, at the time of assessment, which 






With 4.1 million people infected, hepatitis C virus (HCV) is the most prevalent bloodborne viral 
infection in the United States.1,2 HCV is primarily transmitted through shared injection drug use 
(IDU) practices; in fact, prevalence of HCV among people who inject drugs (PWID) ranges 
between 50%-90%.3–6 Between 2010 and 2018, there was a 4.1-fold increase in the reported 
number of cases of acute HCV infection in the US.7,8 This corresponds with increased injection 
drug use among primarily younger, non-urban, white, and female individuals.9,10 Furthermore, 
HIV/HCV coinfection is common and upwards of 90% of HIV-infected PWID are coinfected with 
HCV.3,11 By comparison, the vast majority of HIV/HCV coinfected PWID in the US tend to be 
male, older than 50 years of age, and belong to ethnic minority groups reflective of the earlier 
heroin and cocaine epidemic in the 1980s and 1990s.12,13 
However, HCV is curable and in late 2013, there was a remarkable shift in HCV treatment with 
the advent of direct acting antivirals (DAA).14,15 Between 1991-2013, HCV treatment lasted up to 
48 weeks, included weekly interferon injections, adverse side effects, and cure rates of <50%.16–
18 Today, treatment requires one pill taken daily for 8-12 weeks, minimal side effects, and cure 
rates of >95%.19–23  In the US,  it is projected that by 2030, 80% of all HCV infected individuals 
will be treated.24 However, it is unlikely that access will be comparable across all populations. In 
particular, PWID face greater barriers to access than other groups and between 2015 and 2017, 
it was estimated that only 16% had been treated with DAAs.25,26 In order to effectively improve 
treatment uptake among PWID , it will be important to identify barriers to HCV treatment in this 
new era of DAA-based treatment. 
Barriers to HCV treatment are multifactorial and represent a confluence of individual, provider, 
and system barriers. These were well characterized in the interferon-era of treatment .27,28 In 
particular, low knowledge of HCV and perceptions of treatment-related side effects were 
commonly cited reasons to explain poor initiation of HCV treatment among PWID.27,29,30 
58 
 
Furthermore, studies also found differential knowledge by HIV status.29–32 In the DAA era, 
research has focused primarily on structural barriers given the restrictions placed on 
reimbursement of HCV treatment, particularly from Medicaid. In many settings, these structural 
barriers are dissipating, but less is known about the barriers that will remain.33,34 In order to 
optimally reach all populations at risk for and infected with HCV, it is important to understand 
whether accurate information has penetrated within PWID communities, as it may be facilitator 
for testing or treatment initiation. Some DAA-era studies have found that major gaps in 
knowledge regarding HCV transmission and treatment remain.35,36 However, these studies 
recruited participants from substance use treatment facilities, many of whom offer on-site HCV 
testing and counseling. As such, the results may not be representative of the broader PWID 
community. The aim of this study is to assess the extent to which knowledge of DAAs has 
penetrated the PWID community and assess whether subgroups that had low knowledge of 
interferon continue to have poor knowledge of DAAs. While the focus is on knowledge of DAA-





The AIDS Linked to the IntraVenous Experience (ALIVE) Study is a prospective community-
based cohort of current and former PWID, located in Baltimore, Maryland, which has been 
described previously.37 Participants were recruited independent of engagement in health or 
harm reduction services, through street outreach, flyer distribution, and peer referrals. To be 
eligible, individuals must have been ≥18 years of age and reported a history of injection drug 
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use (IDU). After the initial enrollment during 1988-1989, there have been additional enrollment 
periods in 1994-1995, 1998, 2000, 2005-2008, and 2015-2018.    
This analysis includes persons who were enrolled into the ALIVE cohort from 2015-2018 (in the 
DAA-era). At their baseline visit, trained interviewers collected information on demographics, 
past drug use and medical history using standardized questionnaires. Participants were also 
screened for HIV using an enzyme-linked immunosorbent assay (ELISA) and Geenius HIV 1/2 
Confirmatory Assay (Bio-Rad, Hercules, California) and HCV antibodies, using an ELISA (Ortho 
Clinical Diagnostics, Raritan, NJ). HIV positive participants further received an HIV RNA 
assessment (Roche, Basel, Switzerland) and HCV antibody positive participants received an 
HCV RNA test (Abbott Molecular, Des Plaines, Ill) to confirm active infection vs. clearance vs. 
cure. Participants who were HIV or HCV-positive upon entry were asked to self-report their 
engagement in specialty care, which included HCV treatment history. The enrollment process 
was completed with a second visit two to four weeks later where participants were asked about 
recent drug use, comorbidities, and healthcare utilization, reflective of the previous 6-months. In 
this study, the median time between the baseline and first follow-up visit was 33 days (IQR: 30-
38). All participants were subsequently followed semi-annually.    
Data Collection 
A questionnaire on HCV knowledge was administered to all persons recruited from 2015-2018 
at the baseline visit prior to the provision of counseling and testing related to HCV. The 
questionnaire was adapted from the HCV Follow-Up Questionnaire administered through 
NHANES and included 17 true/false questions to assess participant knowledge.38 Specifically, 
the questions evaluate the participant’s knowledge of HCV transmission (7-questions), natural 
history (5-questions), treatment (3-questions), clinical management (1-question), and prevention 
modalities (1-question). In this analysis we used the responses to questions regarding HCV 
transmission, natural history, and treatment, to generate a knowledge score for each subscale.  
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Additional variables of interest were classified based on laboratory testing and the surveys 
administered at the baseline and first follow-up visit. Those ascertained at the baseline visit, 
include demographic characteristics (i.e. age, sex, race, education level), lifetime needle sharing 
practices and participant’s social network size (i.e. number of known PWID in Baltimore, MD, 
number of known HCV-positive PWID in Baltimore, MD). Those reported at the first follow-up 
visit included self-reported drug use (i.e. frequency of injection drug use, type of drug use), use 
of harm reduction services (i.e. syringe service programs and medication for opioid use 
disorder), and healthcare utilization (i.e. having source of primary care, outpatient visit, visit to 
emergency department). All characteristics ascertained at the first follow-up visit reflect use in 
the previous 6-months. Type of drug use was categorized as none, injection drug use only, non-
injection drug use only, both injection and non-injection drug use. Injection drug use was defined 
as a participant’s self-reported use of heroin, cocaine, speedball (heroin and cocaine) or 
methamphetamine through injection. Non-injection drug use was defined as use of heroin or 
crack use through inhalation. Finally, using ArcGIS, we calculated proximity from the 
participants’ primary residence to the nearest substance use treatment facility, where PWID 
might receive information on HCV and HCV testing, which would be reflected in a higher 
knowledge score. These substance use facilities were identified through the Substance Abuse 
and Mental Health Services Administration (SAMHSA) Behavioral Health Treatment Services 
Locator. The list of facilities is updated annually using responses from SAMHSAs National 
Survey of Substance Abuse Treatment Services (N-SSATS) and National Mental Health 
Services Survey (N-MHSS). Additionally, new facilities that complete abbreviated versions of 
the surveys are added monthly.  
Statistical Analysis 
We used descriptive statistics to compare the sociodemographic and behavioral characteristics 
by participant HCV antibody and HIV status using a chi-square or Fisher’s exact test for 
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categorical variables and a Wilcoxon-Mann-Whitney test for continuous variables. For 
knowledge regarding HCV transmission and natural history of HCV, we dichotomized HCV 
knowledge as either “high” or ‘low” using the highest quartile of the distribution of the number of 
questions answered correctly as the cut-point. Based on the distribution of correct responses, 
our cut-points indicating “high” knowledge related to HCV transmission and natural history were 
86% and 80%, respectively. For HCV treatment knowledge, we classified “high knowledge” as 
correctly answering the three treatment-related questions correctly, and “low knowledge” as 
answering none, one or two of the knowledge questions correctly.  
Separate univariable and multivariable logistic regression models were used to determine 
factors independently associated with high knowledge for each sub-scale. Initial models 
included all participants (N=826) recruited from 2015-2018 and only included covariates 
measured at the baseline visit. Of the 826 who attended the baseline visit, 637 (77%) also 
attended the first follow-up visit where information was collected on recent risk behaviors. Our 
second multivariable analysis also included information that was available for the 637 
participants who returned for the first follow-up visit. Compared to those who did attend this visit, 
participants who did not were more likely to be HCV mono-infected, white, younger, and live 
outside of Baltimore City (p<0.05 for all). There were no statistically significant differences in 
HCV knowledge, lifetime drug use, social network size, or distance to substance use treatment 
facilities among those who did and did not attend the first follow-up visit. To pick our final 
models, we also considered all variables with a p-value ≤0.1 in the univariable analysis. If 
collinearity was detected between variables, we selected the one that was the most 
biologically/clinically meaningful. Variables in the final model were chosen based on an a priori 
hypothesis or because they had been shown to be associated with HCV knowledge in the 
literature. In both multivariable models, basic demographics, education level, proximity to 
services used by PWID, and the number of other PWID that the participant reported knowing 
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were included models, regardless of statistical significance, as they have been shown to be 
associated with HCV knowledge in prior literature. Variables measuring care (i.e. outpatient 
medical visits in the previous 6 months) or service utilization (i.e. prescription of medication for 
opioid use disorder) were retained in the final model because they represented potential 
opportunities for education about HCV that could result in higher knowledge scores. Variables 
were also retained in the final model if they were risk behaviors (i.e. frequency of injection drug 
use, recent injection drug use) that had been associated with low HCV knowledge in other 
studies.31,39  
Because HCV knowledge is likely influenced by engagement in HIV and/or HCV care, additional 
analyses characterized persons by their HIV and HCV care status. First, among HIV/HCV 
coinfected participants, we evaluated differences in each of the knowledge types by whether 
persons had achieved HIV viral suppression. Similarly, among participants who were HCV 
antibody positive, we examined outcomes by three groups: (1) HCV infected, but not diagnosed; 
(2) HCV infected, diagnosed, but not treated; and (3) HCV infected, diagnosed and treated, 





Characteristics of the 826 participants who completed the HCV knowledge questions and 637 
participants who returned for the first follow-up visit are presented in Table 1. Overall, the 
median age was 46 years, 71% were male, 54% were Black, 32% were HCV negative, 54% 
were HCV mono-infected and 14% were HIV/HCV coinfected. Among those who were HCV 
mono-infected and HIV/HCV coinfected, 64.3% and 59.6% reported having a previous positive 
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HCV test. Compared to those who were HCV negative, both HCV mono-infected and HIV/HCV 
coinfected participants were more likely to be older. HCV mono-infected were more likely to be 
white and HIV/HCV coinfected participants were more likely to be Black. Among participants 
who attended the first follow-up visit, HCV mono-infected participants were more likely to be 
prescribed medication for opioid use disorder, with little difference between HIV/HCV coinfected 
and HCV negative participants. Finally, healthcare utilization varied among the groups, where 
nearly all HIV/HCV coinfected participants had at least one outpatient visit, which was 
significantly higher than both HCV mono-infected and HCV negative participants.  
HCV Knowledge Scale 
Table 2 presents the individual items within the HCV knowledge scale, correct responses, and 
the percentage of participants who answered each question correctly by HIV and HCV status. In 
terms of injection-specific transmission knowledge, nearly all participants (99%) were aware that 
HCV is transmitted through sharing needles. While over 91% of both HCV mono-infected and 
HIV/HCV coinfected participants were aware that HCV could be transmitted by sharing works, 
like spoons or cookers, only 84% of HCV negative participants were aware. Responses to the 
natural history questions revealed that nearly all participants were aware that HCV can be 
asymptomatic (97%) and negatively affects your liver (95%), but participants were less familiar 
with the long-term health effects. However, we did see variability in responses between the 
three exposure groups regarding two of the treatment knowledge questions. Knowledge of HCV 
treatment was highest among HIV/HCV coinfected participants (77%), followed by HCV mono-
infected participants (70%) and considerably lower among HCV negative participants (41%).  
HCV Transmission Knowledge  
Overall, 23% were classified as having high HCV transmission knowledge. In the univariable 
analysis, transmission-related knowledge did not differ significantly by HIV or HCV status (Table 
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3). However, transmission-related knowledge was significantly associated with younger age 
(OR: 1.02, 95% CI: 1.01, 1.04), a lifetime history of needle sharing (OR: 1.54, 95% CI: 1.01, 
2.34), increased frequency of injection drug use, and among participants who were Black (OR: 
0.68, 95% CI: 0.48, 0.94). However, no variables were associated (P>0.05) with transmission 
knowledge in either multivariable models.    
HCV Natural History Knowledge  
In total, 31% participants were classified as having a high knowledge of the natural history of 
HCV. In the univariable analysis, there was no statistically significant difference in knowledge of 
HCV natural history by HIV or HCV status (Table 4). However, knowledge was associated with 
having at least a high school diploma, (OR: 1.46, 95% CI: 1.08, 1.98), history of sharing needles 
(OR: 1.86, 95% CI: 1.27, 2.75), and knowing between 10 and 19 other PWID (OR: 1.65, 95% 
CI: 1.02, 2.67) or at least 50 other PWID (OR: 1.82, 95% CI: 1.20, 2.78). In the first multivariable 
analysis, having at least a high school diploma (aOR:1.41, 95% CI: 1.02, 1.95) and history of 
sharing needles (aOR: 2.04, 95% CI: 1.32, 3.15) remained significantly associated with higher 
knowledge. Additionally, female sex was associated with lower knowledge (aOR: 0.66, 95% CI: 
0.46, 0.96). In the second multivariable model, only the association between lifetime history of 
sharing needles (aOR: 1.76, 95% CI: 1.10, 2.83) and high natural history knowledge was 
significant.  
HCV Treatment Knowledge  
Overall, 78% of the ALIVE participants correctly answered the three treatment-related 
questions. In univariable analysis, compared to HCV mono-infected participants, HCV negative 
participants were significantly less likely to have high knowledge of HCV treatment (OR: 0.27, 
95% CI: 0.19, 0.39) (Table 5). Additionally, participants who self-reported injecting drugs in the 
previous 6-months had 50% (95% CI: 0.27, 0.92) lower odds of a high treatment knowledge 
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score. Participants who were prescribed medication for opioid use disorder in the previous 6-
months had 50% (95% CI: 1.02, 2.26) higher odds of high treatment knowledge. In the 
multivariable analyses that accounted for lifetime risk factors (aOR: 0.27, 95% CI: 0.17, 0.39) 
and recent risk behaviors (aOR: 0.22, 95% CI: 0.14, 0.36), the association between being HCV 
negative and lower treatment knowledge persisted. Finally, the association between baseline 
drug use and lower treatment knowledge (aOR: 0.51, 95% CI: 0.26, 0.98) was statistically 
significant, but the association between drug use at follow-up and treatment knowledge as not. 
HCV Knowledge among Subgroups of PWID 
When evaluating whether HCV knowledge differed among HIV positive PWID by HIV viral 
suppression, we observed no differences (Supplemental Table 1a). Similarly, among HCV-
infected participants, knowledge of HCV transmission or natural history did not appear to vary 
by engagement in HCV care. However, knowledge of HCV treatment was significantly higher 
among participants who were aware of their HCV-positive status or treated for HCV in the past 
(Supplemental Table 1b). After restricting the analysis, results showed that participants who 
were diagnosed with HCV prior to entering the study, but not treated, had over 3-times the odds 
of high treatment knowledge, compared to those who were not diagnosed before their baseline 
visit, in both multivariable models (Supplemental Table 2).   
 
DISCUSSION 
Our study showed that, overall, HCV knowledge among this population of people who inject 
drugs (PWID) is high, although critical gaps remain. Encouragingly, nearly all participants were 
aware of which injection-related drug use practices contributed to HCV transmission. Likewise, 
nearly all participants were aware that HCV could negatively affect your liver over time, but two-
thirds correctly estimated the percentage of people who would develop liver cancer or liver 
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disease, similar to findings from the interferon era.40–42 We observed substantial improvement 
with respect to HCV treatment knowledge with 80% of the participants correctly answering that 
HCV is curable. This was remarkably higher than results from a prior study among ALIVE 
participants in the interferon-era, which found that 70% were aware that treatment was 
available, but only one-fifth of those correctly answered that HCV is curable.27 Despite this 
marked improvement, a relatively high percentage of participants had incorrect beliefs regarding 
treatment duration or side effects. This is likely representative of residual misinformation about 
changes between interferon-based and DAA treatment. If so, these results suggest specific 
HCV-related topics that should be highlighted in education efforts for PWID. 
In addition to assessing overall gaps in knowledge, we identified some factors that could be 
considered facilitators to obtaining knowledge of DAAs, specifically. It was encouraging that 
HCV treatment knowledge was higher among those who were aware of their HCV infection prior 
to completing the survey. In fact, this has also been observed in other studies, which found that 
HCV knowledge was higher among HCV infected PWID who were either diagnosed, evaluated 
or treated before an HCV knowledge assessment.31,32,43 This suggests that people are being 
counseled about treatment at the point of testing or at some point afterwards, which is critical for 
effective linkage to care. Additionally, PWID may be more receptive to information regarding 
treatment after they are diagnosed with HCV, when it is perceived to be more relevant. 
However, in this population between 35% and 40% of those who were HCV infected were 
unaware of their infection at study entry. This stresses the importance of ensuring adequate 
information about HCV transmission risk and treatment is available to all PWID, as many are not 
yet aware of their status and some may acquire HCV in the future.   
We hypothesized that proximity and usage of services and social network size could impact 
HCV knowledge because contact with people or these systems have the potential for 
knowledge provision. In fact, this has been confirmed in both interferon and DAA-era studies 
67 
 
among PWID.31,42–48 While we failed to detect associations between service utilization, social 
network size and knowledge of HCV transmission, we did observe that a larger social network 
size and prescription of medication for opioid use disorder were associated with higher 
knowledge of HCV natural history and treatment, respectively. Our study did not capture 
whether participants attribute their HCV knowledge to either of these mechanisms, but these 
associations may still provide some insight into places where PWID can obtain knowledge. 
However, it should be noted that the measure of healthcare utilization and treatment for opioid 
use capture usage within the past six months only and it is possible that a participant could have 
received HCV education more than six months ago.    
To achieve HCV elimination goals in the United States, there have been widespread campaigns 
to improve awareness of HCV, its sequalae, and treatment modalities, including at services that 
are frequented by PWID. However, the quality of education across these settings may vary. Our 
study supports that knowledge among PWID has substantially increased soon after the 
availability of DAAs. At the same time, our study also demonstrated that residual information 
related to interferon-based treatment remains. These results can be used to update HCV 
education materials that are not only tailored to PWID, but also healthcare professionals and 
other direct service providers who work with PWID. For example, updated education materials 
could highlight that DAA-based therapies have shorter duration, fewer frequency of treatment-
related side effects and the low pill burden, compared to interferon-based therapies. 
Our study is not without limitations. First, participants were not asked where or when they 
received HCV education, which impacts our ability to draw conclusions regarding utilization of 
services and HCV knowledge. Second, while HIV and HCV status are laboratory confirmed, 
participants self-report drug use practices, engagement in HCV care, and HCV treatment 
history. We do not anticipate this to bias our results, as previous studies in ALIVE have shown 
high validity and reliability of participants’ self-report drug use.49 There is the potential for 
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selection bias, as HCV mono-infected participants were less likely to return for the first follow-up 
visit. We addressed this by performing a multivariable regression using variables from the 
baseline visit, which did not change any of our findings. Finally, since this study was conducted 
in a large cohort study, our findings may not be generalizable to other areas or broader PWID 
community in Baltimore, MD. However, since HCV knowledge questions are asked prior to the 
receipt of HCV counseling at ALIVE, we believe that baseline knowledge is likely generally 
representative to that of PWID in Baltimore.  
 
Despite the availability of DAAs, HCV treatment uptake among PWID in the US remains low. In 
the interferon-era poor knowledge of HCV was a common barrier among PWID. Our study 
showed an improvement in PWID knowledge, but misinformation remains, which could be a 
contributing factor as to why treatment uptake remains low today. Our study results can help 
modernize HCV education and focus these initiatives to groups at high-risk of poor HCV 
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N 447 264 115   
Demographic Characteristics1     
Age (year), median (IQR) 47.0 (37.8, 54.3) 41.4 (31.0, 48.4) 53.2 (45.5, 57.9) <0.01 
Female sex 139 (31.1%) 62 (23.5%) 36 (31.3%) 0.08 
Black race 212 (47.4%) 142 (53.8%) 93 (80.9%) <0.01 
Education level ≥high school diploma 233 (52.1%) 151 (57.2%) 52 (45.6%) 0.11 
Social Network Factors1     
Number of known PWID in Baltimore City       
   0-9 89 (19.9%) 61 (23.1%) 24 (20.9%) 
0.17 
   0-19 84 (18.8%) 53 (20.1%) 17 (14.8%) 
   20-49 107 (23.9%) 74 (28.0%) 25 (21.7%) 
   ≥50 167 (37.4%) 76 (28.8%) 49 (42.6%) 
Number of known PWID with HCV infection in Baltimore City      
 
   0-1 112 (25.3%) 60 (23.1%) 30 (26.1%) 
0.94 
   2-4 100 (22.6%) 67 (25.8%) 30 (26.1%) 
   5-14 114 (25.7%) 68 (26.2%) 28 (24.3%) 
  ≥15 117 (26.4%) 65 (25.0%) 27 (23.5%) 
Drug Use Behaviors     
Any injection drug use1 392 (89.3%) 233 (89.3%) 88 (78.6%) <0.01 
Type of drug use2         
   None 34 (11.6%) 10 (5.5%) 16 (16.3%) 
<0.01 
   Injection drug use only3 31 (10.6%) 15 (8.2%) 9 (9.2%) 
   Non-injection drug use only4 30 (10.2%) 20 (10.9%) 26 (26.5%) 
   Injection drug use and non-injection drug use 198 (67.6%) 138 (75.4%) 47 (48.0%) 
Frequency of injection drug use2        
   None 59 (18.3%) 35 (17.0%) 37 (35.2%) 
<0.01 
 
   Less than daily 110 (34.1%) 70 (34.0%) 31 (29.5%) 
   Daily 154 (47.7%) 101 (49.0%) 37 (35.2%) 
Prescribed medication for opioid use disorder2 245 (75.2%) 130 (63.1%) 67 (63.8%) <0.01 
Visited syringe services program2 134 (41.7%) 86 (41.7%) 38 (36.2%) 0.57 
Ever shared needles1 372 (83.4%) 167 (63.7%) 98 (85.2%) <0.01 
Healthcare Utilization2     
Had a primary care provider 247 (76.0%) 156 (75.7%) 101 (96.2%) <0.01 
Outpatient visit 212 (65.0%) 132 (64.1%) 97 (93.3%) <0.01 
Emergency department visit 145 (44.8%) 86 (41.7%) 50 (47.6%) 0.59 
Proximity to Harm Reduction1     
Closest substance use treatment facility (km), median (IQR) 0.5 (0.2, 1.0) 0.5 (0.2, 1.1) 0.4 (0.2, 0.8) 0.22 
HCV Care Continuum        
Ever tested for HCV 427 (96.4%) 234 (90.4%) 109 (95.6%) <0.01 
Ever tested HCV positive 274 (64.3%)  65 (59.6%) <0.01 
Evaluated by a medical provider that treats HCV 104 (54.7%)   40 (81.6%)  <0.01 
Ever treated for HCV 36 (8.2%)  31 (27.9%) <0.01 
Completion of Previous Treatment and Successfully Cured5 2 (22.2%)  2 (66.7%) 0.38 
1From baseline visit (N-826) 
2From follow-up visit (N=637) and reflective of 6 months prior to study visit 
3Includes injection of heroin, cocaine, speedball (heroin and cocaine together), methamphetamine or any other type of drug 
4Includes smoking crack or heroin 
5Of the HCV mono-infected participants, 1 (50%) participant who self-reported being cured had an undetectable HCV viral load 


















Transmission Subscale1       
You can get hepatitis C by kissing someone who has 
hepatitis C False 635 (77.5%) 176 (68.2%) 363 (81.9%) 94 (82.5%) <0.01 
You can get hepatitis C by having sex with someone who 
has hepatitis C if there is no blood to blood contact False 387 (47.2%) 113 (43.6%) 219 (49.4%) 54 (47.4%) 0.33 
You can get hepatitis C by being stuck with a needle or 
sharp instrument that has hepatitis C infected blood on it True 798 (97.3%) 254 (98.1%) 430 (97.1%) 110 (96.5%) 0.62 
You can get hepatitis C by sharing injecting needles, 
syringes, with someone who has hepatitis C, even if only a 
few times True 808 (98.5%) 256 (98.8%) 436 (98.4%) 112 (98.2%) 0.87 
You can get hepatitis C by sharing injecting spoons, water 
or cookers with someone who has hepatitis C, even if only 
a few times True 732 (89.3%) 218 (84.2%) 406 (91.6%) 106 (93.0%) <0.01 
You can get hepatitis C by getting a blood transfusion from 
an infected donor True 789 (96.2%) 252 (97.3%) 423 (95.5%) 110 (96.5%) 0.47 
You can get hepatitis C by being born to a woman who had 
hepatitis C when she gave birth True 563 (68.7%) 184 (71.0%) 301 (67.9%) 75 (65.8%) 0.54 
Natural History Subscale2       
Someone with hepatitis C can look and feel fine True 797 (97.4%) 249 (96.1%) 432 (97.5%) 112 (99.1%) 0.21 
If someone is infected with the hepatitis C virus, they will 
most likely carry the virus all their lives True 479 (58.6%) 158 (61.0%) 255 (57.6%) 63 (56.3%) 0.60 
Infection with the hepatitis C virus can cause the liver to 
stop working True 779 (95.3%) 237 (91.9%) 429 (97.1%) 109 (96.5%) <0.01 
Someone with a positive hepatitis C antibody result today 
can test negative for hepatitis C antibodies in the future False 217 (26.6%) 77 (29.7%) 103 (23.4%) 36 (31.9%) 0.07 
Almost everyone with chronic hepatitis C infection will 
develop liver failure or liver cancer in the future False 288 (35.3%) 89 (34.4%) 162 (36.7%) 36 (31.9%) 0.58 
Treatment Subscale3       
Hepatitis C infection can be cured True 653 (79.9%) 172 (66.4%) 376 (85.6%) 102 (91.1%) <0.01 
Hepatitis C treatments cause bad side effects in almost 
everyone who takes them False 489 (59.9%) 137 (52.9%) 276 (62.6%) 74 (65.5%) 0.02 
Hepatitis C can be cured with just a couple of pills a day 
taken for 12 weeks True 503 (61.6%) 106 (40.9%) 307 (69.6%) 87 (77.0%) <0.01 
People who inject drugs should get the hepatitis A and B 
vaccine whether or not they have hepatitis C True 675 (82.5%) 205 (79.2%) 366 (82.8%) 101 (89.4%) 0.06 
A hepatitis C vaccine is available False 76 (9.3%) 25 (9.7%) 42 (9.5%) 8 (7.1%) 0.70 
1The cut-point for a high knowledge score was 86% and 23% of those who completed the HCV assessment had high transmission knowledge 
2The cut-point for a high knowledge score was 80% and 31% of those who completed the HCV assessment had high natural history knowledge 
3The cut-point for a high knowledge score was answering all 3-questions correctly, and 78% of those who completed the HCV assessment had 
high treatment knowledge 
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Table 3.  Correlates of relatively high HCV transmission knowledge1 among participants of ALIVE study by HIV and HCV status, 
Baltimore, MD, 2015-2018 
  Univariable Analysis Baseline Model2 Follow-Up Model3 
 OR (95% Conf. Interval) aOR (95% Conf. Interval) aOR (95% Conf. Interval) 
HCV and HIV status4       
   HCV mono-infected REF REF REF 
   HCV negative 0.77 (0.53, 1.12) 0.71 (0.46, 1.07) 0.73 (0.46, 1.18) 
   HIV/HCV coinfected 0.74 (0.45, 1.22) 0.86 (0.49, 1.49) 0.91 (0.50, 1.64) 
Age (year)4 0.98 (0.96, 0.99) 0.98 (0.96, 1.00) 0.98 (0.96, 1.00) 
Participant's sex4     
   Male REF REF REF 
   Female 0.96 (0.67, 1.37) 0.99 (0.67, 1.46) 0.91 (0.59, 1.41) 
Participant's race4       
   Non-Black REF REF REF 
   Black 0.68 (0.48, 0.94) 0.95 (0.63, 1.43) 1.01 (0.64, 1.60) 
≥High school diploma4       
   No REF REF REF 
   Yes 1.12 (0.81, 1.54) 1.01 (0.71, 1.43) 1.04 (0.70, 1.55) 
Ever shared needles4    
   No REF REF REF 
   Yes 1.54 (1.01, 2.34) 1.39 (0.87, 2.21) 1.35 (0.80, 2.28) 
Number of known PWID in Baltimore City4       
   0-9 REF REF REF 
  10-19 1.59 (0.97, 2.61) 1.57 (0.92, 2.68) 1.56 (0.87, 2.80) 
   20-49 1.10 (0.68, 1.79) 1.10 (0.65, 1.85) 0.96 (0.54, 1.72) 
   >=50 0.90 (0.57, 1.43) 0.88 (0.53, 1.46) 0.66 (0.37, 1.16) 
Any injection drug use      
   No  REF REF  
   Yes 1.70 (0.97, 2.98) 1.26 (0.70, 2.27)   
Injection drug use frequency     
   None REF   REF 
   Less than daily 1.81 (1.02, 3.21)   1.49 (0.82, 2.70) 
   Daily 1.85 (1.07, 3.19)   1.50 (0.84, 2.68) 
Prescribed of medication for opioid use disorder      
   No REF   REF 
   Yes 1.21 (0.80, 1.84)  1.05 (0.67, 1.63) 
Outpatient visit     
   No REF   REF 
   Yes 0.86 (0.58, 1.29)  1.05 (0.67, 1.64) 
Closest substance use treatment facility (km)4 0.98 (0.87, 1.11) 0.93 (0.81, 1.07) 0.90 (0.75, 1.08) 
1Knowledge score was generated from 7 transmission-related questions out of 17-item HCV knowledge scale. The cut-point for a high 
knowledge score was 86% and 23% of those who completed the HCV assessment had high transmission knowledge 
2Model includes variables that were collected at baseline visit (N-826) 
3Model contains variables that were collected at follow-up visit (N=637) and reflective of 6 months prior to study visit 











Table 4.  Correlates of relatively high HCV natural history knowledge1 among participants of ALIVE study by HIV and HCV status, 
Baltimore, MD, 2015-2018 
  Univariable Baseline Model2 Follow-Up Model3 
  OR (95% Conf. Interval) aOR (95% Conf. Interval) aOR (95% Conf. Interval) 
HCV and HIV status4     
   HCV mono-infected REF REF REF 
   HCV negative 1.12 (0.81, 1.56) 1.35 (0.93, 1.97) 1.33 (0.87, 2.03) 
   HIV/HCV coinfected 1.03 (0.66, 1.61) 0.96 (0.59, 1.56) 0.86 (0.51, 1.45) 
Age (year)4 1.00 (0.99, 1.02) 1.01 (1.00, 1.03) 1.00 (0.99, 1.03) 
Participant's sex4    
   Male REF REF REF 
   Female 0.71 (0.51, 1.00) 0.66 (0.46, 0.96) 0.72 (0.48, 1.07) 
Participant's race4    
   Non-Black REF REF REF 
   Black 0.85 (0.63, 1.15) 0.88 (0.60, 1.28) 0.82 (0.54, 1.25) 
≥High school diploma4    
   No REF REF REF 
   Yes 1.46 (1.08, 1.98) 1.41 (1.02, 1.95) 1.31 (0.92, 1.87) 
Ever shared needles4    
   No REF REF REF 
   Yes 1.86 (1.27, 2.75) 2.04 (1.32, 3.15) 1.76 (1.10, 2.83) 
Number of known PWID in Baltimore City4    
   0-9 REF REF REF 
  10-19 1.65 (1.02, 2.67) 1.51 (0.91, 2.52) 1.53 (0.87, 2.70) 
   20-49 1.16 (0.73, 1.85) 1.11 (0.68, 1.81) 1.14 (0.66, 1.98) 
   >=50 1.82 (1.20, 2.78) 1.53 (0.97, 2.42) 1.38 (0.83, 2.29) 
Any injection drug use    
   No  REF REF  
   Yes 1.01 (0.64, 1.59) 1.01 (0.62, 1.66) 
Injection drug use frequency    
   None REF  REF 
   Less than daily 0.85 (0.53, 1.34)  0.86 (0.52, 1.40) 
   Daily 0.73 (0.47, 1.13)  0.77 (0.48, 1.25) 
Prescribed of medication for opioid use disorder     
   No REF  REF 
   Yes 0.76 (0.53, 1.08)  0.68 (0.46, 1.01) 
Outpatient visit    
   No REF  REF 
   Yes 1.44 (0.99, 2.10)  1.49 (0.98, 2.29) 
Closest substance use treatment facility (km)4 0.97 (0.86, 1.09) 0.95 (0.84, 1.08) 0.96 (0.85, 1.09) 
1Knowledge score generated from 5 natural history related questions out of 17-item HCV knowledge scale. The cut-point for a high 
knowledge score was 80% and 31% of those who completed the HCV assessment had high natural history knowledge 
2Model includes variables that were collected at baseline visit (N-826) 
3Model contains variables that were collected at follow-up visit (N=637) and reflective of 6 months prior to study visit 





Table 5.  Correlates of high HCV treatment knowledge1 among participants of ALIVE study by HIV and HCV status, Baltimore, MD, 2015-
2018  
  Univariable Baseline Model2 Follow-Up Model3 
  OR (95% Conf. Interval) aOR (95% Conf. Interval) aOR (95% Conf. Interval) 
HCV and HIV status4      
   HCV mono-infected REF REF REF 
   HCV negative 0.27 (0.19, 0.39) 0.26 (0.17, 0.39) 0.22 (0.14, 0.36) 
   HIV/HCV coinfected 1.63 (0.83, 3.20) 1.46 (0.73, 2.94) 1.40 (0.67, 2.91) 
Age (year)4 1.02 (1.00, 1.03) 1.00 (0.98, 1.02) 1.00 (0.98, 1.03) 
Participant's sex4    
   Male REF REF REF 
   Female 1.02 (0.71, 1.47) 0.95 (0.63, 1.43) 1.05 (0.66, 1.66) 
Participant's race4    
   Non-Black REF REF REF 
   Black 0.92 (0.65, 1.29) 0.90 (0.58, 1.39) 0.83 (0.51, 1.36) 
≥High school diploma4    
   No REF REF REF 
   Yes 1.03 (0.74, 1.44) 1.08 (0.74, 1.56) 1.16 (0.76, 1.76) 
Ever shared needles4    
   No REF REF REF 
   Yes 1.70 (1.17, 2.47) 1.06 (0.68, 1.64) 1.06 (0.64, 1.74) 
Number of known PWID in Baltimore City4    
   0-9 REF REF REF 
  10-19 0.89 (0.53, 1.49) 0.83 (0.47, 1.46) 0.80 (0.41, 1.55) 
   20-49 0.83 (0.51, 1.35) 0.85 (0.49, 1.45) 0.74 (0.39, 1.39) 
   >=50 1.13 (0.71, 1.81) 0.93 (0.55, 1.56) 0.79 (0.44, 1.44) 
Any injection drug use    
   No  REF REF  
   Yes 0.50 (0.27, 0.92) 0.51 (0.26, 0.98)  
Injection drug use frequency    
   None REF  REF 
   Less than daily 0.69 (0.40, 1.19)  0.70 (0.38, 1.28) 
   Daily 0.74 (0.43, 1.25)  0.78 (0.43, 1.40) 
Prescribed of medication for opioid use disorder    
   No REF  REF 
   Yes 1.51 (1.02, 2.26)  1.35 (0.87, 2.11) 
Outpatient visit    
   No REF  REF 
   Yes 0.89 (0.59, 1.36)  0.68 (0.42, 1.10) 
Closest substance use treatment facility (km)4 0.98 (0.87, 1.09) 1.01 (0.90, 1.13) 0.98 (0.86, 1.11) 
1Knowledge score generated from 3 treatment-related questions out of 17-item HCV knowledge scale. The cut-point for a high knowledge 
score was answering all 3-questions correctly, and 78% of those who completed the HCV assessment had high treatment knowledge 
2Model includes variables that were collected at baseline visit (N-826) 
3Model contains variables that were collected at follow-up visit (N=637) and reflective of 6 months prior to study visit 















High Transmission Knowledge 87 (22.3%) 81 (26.8%) 8 (20.5%) 0.33 
High Natural History Knowledge 121 (31.0%) 98 (32.6%) 11 (28.2%) 0.82 
High Treatment Knowledge 272 (69.6%) 263 (87.4%) 38 (97.4%) <0.01 
 
  
Supplemental Table 1a. Proportion of participants with HIV/HCV coinfection with high HCV knowledge by HIV viral 
suppression 
Knowledge Scale Undetectable HIV Viral Load Detectable HIV Viral Load p-value 
High Transmission Knowledge 11 (22.0%) 12 (15.6%) 0.36 
High Natural History Knowledge 15 (30.6%) 26 (33.8%) 0.71 





Supplemental Table 2. Correlates of high HCV treatment knowledge1 among HCV-infected participants by 
awareness of HCV status upon study entry, Baltimore, MD, 2015-2018 
  Baseline Model2 Follow-up Model3 
  aOR (95% Conf. Interval) aOR (95% Conf. Interval) 
HCV status upon study entry4    
   HCV infected, not diagnosed REF REF 
   HCV infected, diagnosed, not treated 3.00 (1.93, 4.66) 3.05 (1.86, 5.00) 
Age (year)4 1.01 (0.99, 1.03) 1.03 (1.00, 1.05) 
Participant's sex4   
   Male REF REF 
   Female 0.96 (0.62, 1.48) 1.13 (0.69, 1.85) 
Participant's race4   
   Non-Black REF REF 
   Black 0.84 (0.54, 1.32) 0.73 (0.43, 1.21) 
≥High school diploma4   
   No REF REF 
   Yes 1.00 (0.67, 1.47) 1.12 (0.72, 1.75) 
Ever shared needles4   
   No REF REF 
   Yes 1.24 (0.78, 1.96) 1.19 (0.71, 2.01) 
Number of known PWID in Baltimore City4   
   0-9 REF REF 
  10-19 0.56 (0.30, 1.06) 0.50 (0.24, 1.04) 
   20-49 0.58 (0.32, 1.07) 0.48 (0.24, 0.97) 
   >=50 0.63 (0.35, 1.13) 0.51 (0.26, 1.00) 
Any injection drug use   
   No  REF  
   Yes 0.57 (0.29, 1.12)  
Injection drug use frequency   
   None  REF 
   Less than daily  0.75 (0.40, 1.41) 
   Daily  0.77 (0.41, 1.43) 
Prescribed of medication for opioid use disorder   
   No  REF 
   Yes  1.44 (0.90, 2.30) 
Outpatient visit   
   No  REF 
   Yes  0.58 (0.35, 0.99) 
Closest substance use treatment facility (km)4 1.03 (0.90, 1.17) 1.00 (0.87, 1.14) 
1Knowledge score generated from 3 treatment-related questions out of 17-item HCV knowledge scale and 
is based on highest quartile of responses. % with high knowledge 
2Model includes variables that were collected at baseline visit (N-826) 
3Model contains variables that were collected at follow-up visit (N=637) and reflective of 6 months prior to 
study visit 
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Background: HCV treatment uptake among people who inject drugs (PWID) was low in the 
interferon-era and barriers to treatment were well characterized. With the availability of direct 
acting antivirals (DAA), treatment uptake among PWID has improved. But as evident by the 
increasing incidence of acute HCV infection, subgroups of PWID are missed.  
Methods: We evaluated cumulative HCV treatment uptake among 1,146 HCV-antibody positive 
participants of the ALIVE study, a community-based cohort of current and former PWID, who 
were eligible for HCV treatment and had at least one visit between 2011 and 2019. We first 
calculated the cumulative proportion of HCV treatment uptake and treatment rate for each year 
of the study to understand temporal trends over time. Subsequently, we categorized the study 
period into three eras of HCV treatment, the interferon-era (2011-2013), the early DAA-era 
(2014-2016), and late DAA-era (2017-2018) to evaluate how characteristics of participants 
treated changed. Finally, we performed a Poisson regression analysis to identify predictors of 
HCV treatment uptake in each era.  
Results:  The cumulative proportion of HCV treatment uptake increased from 15% in the 
interferon-era to 70% the late DAA-era. The greatest improvement was seen in the DAA-era, 
from 2014-2019, where the rate of HCV treatment uptake improved from 0.68 per 100 person-
years in 2014 to 6.63 per 100 person-years in 2019. In the interferon-era, education level was 
the main predictor of treatment uptake (IRR: 2.69, 95% CI: 1.27, 5.73). In the early DAA-era, 
predictors of treatment uptake included older age (IRR: 1.05, 95% CI: 1.02, 1.07), having a 
recent outpatient visit (IRR: 1.15, 95% CI: 1.34, 3.76), having HIV/HCV coinfection with an 
undetectable HIV viral load (IRR: 1.87, 95% CI: 1.42, 2.48), and having cirrhosis (IRR: 1.64, 
95% CI: 1.16, 2.32). In the late DAA-era, the main predictors of treatment uptake were being 
HIV/HCV coinfected with a detectable HIV viral load (IRR: 0.35, 95% CI: 0.16, 0.77) and having 
81 
 
a recent outpatient visit (IRR: 2.24, 95% CI: 1.56, 3.77). Daily injection drug use (IRR: 0.60, 
95% CI: 0.38, 0.97) was a predictor in the univariable analysis, but the association did not 
persist in the adjusted analysis.  
Conclusion: Treatment uptake improved remarkably over the entire study period. Those at-risk 
of poor treatment uptake today include PWID that are disconnected from the healthcare system 
and injecting drugs daily. These PWID are at the highest risk of HCV transmission and 






Hepatitis C virus (HCV) is the most prevalent bloodborne viral infection in the United States.1,2 
Injection drug use (IDU) remains the most common mode of transmission and prevalence of 
HCV among people who inject drugs (PWID) is upwards of 90%.3–5 Prevalence of HCV is 
highest among those born between 1945 and 1965, many of whom are former PWID, older, 
minority, and live in urban areas. These individuals were infected when HCV incidence peaked 
in 1980s and 1990s and are now experiencing the long-term complications of HCV-related 
morbidity and mortality.6,7 From 1992 to 2005, HCV incidence declined, largely due to primary 
prevention measures, like screening of blood donations and syringe service programs. After 
plateauing for 5-years, HCV incidence has increased steadily since 2010. In fact, between 2010 
and 2018 incident cases of acute HCV infection more than quadrupled.8–10 These cases are 
primarily attributed to shared injection practices, among a younger, increasingly female, and 
white population who live in suburban and rural areas of the US.11,12  
However, HCV is curable and in 2014, remarkable new therapeutics, direct acting antivirals 
(DAA), became available.13,14 DAA-based treatment requires a single pill, taken daily, for as little 
as 8-weeks, resulting in minimal adverse events, and cure rates of >98%.15–19 Conversely, prior 
to late 2013, HCV treatment required weekly injections of interferon and high pill burden, which 
resulted in serious adverse events that were experienced by >75% of those who were 
treated.20–22 Furthermore, treatment could last for up to 48-weeks and roughly half of those who 
started interferon-based treatment were cured.20,21 Because of the burden of HCV in the United 
States and availability of DAAs, in 2015, the World Health Organization and National Academies 
of Sciences, Engineering, and Medicine released two goals to achieve HCV elimination globally 
and in the United States by 2030: to decrease HCV incidence by 90% and HCV-related 
mortality by 65%.23,24  
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Treatment uptake with interferon-based therapies was low among PWID.25–28 In addition to fear 
of treatment-related side effects, PWID experienced additional barriers, such as stigma, 
provider willingness, poor knowledge of treatment, and competing priorities.29,30 As a result, 
many chose to forego treatment altogether or wait until more effective and better tolerated 
therapies became available. However, due to their high cost, most state Medicaid plans quickly 
implemented restrictions that limited access to DAAs in 2014.31  While implementation of these 
restrictions was variable across states, they included documentation of advanced liver fibrosis; 
6-months abstinence of substance use; and HCV medication could only be prescribed through a 
hepatologist, gastroenterologist or infectious disease specialist. Since then, insurance 
restrictions have relaxed in many states, in part due to pressure from advocacy groups, legal 
action, and a growing evidence-base showing the benefits of treating those with mild and 
moderate fibrosis. For example, in 2017, Maryland’s Medicaid plan removed the 6-month 
sobriety restriction and enabled primary care providers and other non-infectious disease 
specialists to prescribe HCV medication.31 Two years later, they reduced the fibrosis cut-off for 
Medicaid reimbursement from moderate fibrosis to mild.31,32  
Treatment uptake among PWID has improved in areas where insurance restrictions were 
relaxed and among those who are engaged in specialty healthcare or PWID-related services.33–
36 But there are still groups with limited access. Studies evaluating barriers to DAA treatment 
initially focused on structural barriers relating to early insurance restrictions, but have since 
expanded to include both provider and patient-level factors.37–40  However, this body of research 
has focused largely on persons in care and consistently miss PWID who are disconnected from 
these types of services. Certain barriers from the interferon-era, like stigma and distrust of the 
healthcare system, likely persisted into the DAA-era. But it is possible that other individual-level 
barriers between the groups are different. As a result, the aim of our study is to evaluate 
temporal trends in HCV treatment uptake between 2011 and 2019 among a community-based 
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cohort of PWID to identify ongoing individual-level barriers to treatment, even as restrictions to 




The ALIVE (AIDS Linked to the IntraVenous Experience) Study is a community-based cohort of 
current and former PWID, ongoing since 1988 and previously described elsewhere.41 As a 
community-based cohort, participants are recruited primarily through street outreach, flyer 
distribution and peer referrals. Recruitment has spanned more than three decades: 1988-1989 
(N=2,946), 1994-1995 (N=434), 1997-1998 (N=295), 2005-2008 (N=1,009), and 2015-2018 
(N=674). Eligible participants are ≥18 years of age with a history of injection drug use. In total, 
5,358 individuals have been enrolled in ALIVE. This analysis includes 1,146 HCV-antibody 
positive participants who had at least one study visit 2011-2019 and had either a positive HCV 
RNA test or self-reported HCV treatment.  
Data Measurement 
At entry into the cohort, ALIVE participants self-reported demographic characteristics, lifetime 
drug use, and medical history. Subsequently, participants were followed semi-annually, at which 
time they were asked about drug use, comorbidities, and healthcare utilization within the 
previous 6-months, frequency of IDU within the past 30 days, and a FibroScan was performed 
on all participants to measure liver stiffness (fibrosis).42 Results were categorized as: no or mild 
fibrosis (<8 kPa), significant fibrosis (8 kPa-12.3 kPa), or cirrhosis (>12.3 kPa).43,44 For this 
study, we considered sociodemographic characteristics (e.g., sex, race, age, education level, 
and homelessness status) as they had been previously associated with treatment uptake, 
variables that captured the insurance restrictions (e.g., fibrosis score, type of insurance, and 
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recent drug use), services associated with improved treatment uptake (e.g., outpatient medical 
visits, HIV specialty care, prescription of medication for opioid use disorder) and medical 
comorbidities, a known barrier to treatment in the past.29,30,34,39,45–54 All variables, except 
sociodemographic characteristics reflect use in the previous 6-months. A participant was 
considered homeless if they self-reported being displaced for at least one night. An 
undetectable HIV viral load was used as an indicator for engagement in HIV specialty care, 
among participants who were HIV/HCV coinfected. To quantify medical comorbidities, we 
created a health index based on the number of chronic conditions that a participant reported 
having at each visit, including diabetes, seizures, high cholesterol, hypertension, stoke, kidney 
disease, chronic lung disease, depression, anxiety, bipolar disorder or schizophrenia. To 
measure depression, we used participant responses to the 20-item Center for Epidemiologic 
Studies – Depression (CESD) survey to measure depressive symptoms in the previous 
week.56,57 A score of 23 or greater indicated severe depressive symptomology.57 Participants 
were screened for HIV at each study visit using an enzyme-linked immunosorbent assay 
(ELISA) and Geenius HIV 1/2 Confirmatory Assay (Bio-Rad, Hercules, California). An HIV RNA 
test (Roche, Basel, Switzerland) was performed on HIV-positive participants at each visit to 
determine HIV viral suppression (≤50 copies/mL). All participants were screened for HCV 
antibodies using an ELISA (Ortho Clinical Diagnostics, Raritan, NJ) and an HCV RNA test 
(Abbott Molecular, Des Plaines, Ill) confirmed chronicity. HCV RNA testing was conducted 
annually on HCV-positive participants with additional testing to confirm cure among participants 
who self-reported initiating HCV treatment between visits. 
Outcome Ascertainment 
The outcome of interest, HCV treatment, was based on whether a participant self-reported 
being treated for HCV, either “ever” or “in the last 6-months.” There was some variability in this 
measurement over time. Prior to June 2013, participants were only asked about HCV treatment 
86 
 
if they reported being aware of treatment and that they had been offered treatment by a medical 
provider. Beginning in June 2013, all participants, regardless of confirmed HCV status, 
awareness of treatment or a provider offer of treatment were asked if they received HCV 
treatment. Throughout the study period, participants were asked if they were “ever” treated for 
HCV or treated “in the last 6-months,” at baseline and follow-up visits, respectively. A follow-up 
question was added in 2013 and only asked to participants who reported “ever” treated at their 
baseline visit, clarifying if treatment was in the 6-months prior to that visit. For the purposes of 
this study, participants who reported being treated “in the last 6-months” (at either baseline or 
follow-up visits) were considered treated during follow-up. Participants who only reported being 
“ever” treated were considered treated before our analysis.  
Statistical Analysis 
We used descriptive statistics to characterize participants with ALIVE study visits between 2011 
and 2019 using a Chi-square or Fisher’s exact test to compare categorical variables and a 
Wilcoxon-Mann-Whitney test for continuous variables. First, we compared the 
sociodemographic, drug use, and health-related characteristics of people who reported 
treatment prior to our analysis (N=84), to those treated during follow-up (N=488), and those 
never treated for HCV (N=574). In order to evaluate how characteristics of those treated for 
HCV during the study period changed, we restricted the sample to participants that reported 
being treated during follow-up and compared the same characteristics for three time-periods. 
These periods were chosen to capture treatment uptake in the different eras of HCV treatment 
modalities: the interferon (INF) era (2011-2013), when treatment required interferon injections; 
early in the availability of DAAs (2014-2016) when insurance companies had the harshest 
restrictions, which included a sobriety window, prescription of medication by a specialist, and 
documentation of advanced liver disease; and the later DAA-era (2017-2019) when the sobriety 
and specialist restrictions were removed and the fibrosis restriction was relaxed. For participants 
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who had two or more visits per year, we used drug use, healthcare utilization, and comorbidities 
reported at the first visit. If a participant had a visit in January or February, they were considered 
treated in the previous calendar year.  
To evaluate temporal changes in treatment uptake, we calculated cumulative treatment uptake 
both as the proportion of those treated and as a rate per person-time for each year of study 
period. First, we calculated the cumulative proportion of participants who reported being treated 
for each year. The denominator included all those eligible for treatment, as well as, those 
treated in the year, plus those who reported treatment in prior years of the study period. The 
numerator included the people who reported treatment at a visit in the year, plus all in the years 
prior, totaling 572 for the entire study period. When calculating the annual treatment rate, we 
excluded participants who were treated prior to our analysis. The denominator was the person-
years of follow-up time between study visits for each year, contributed by all those who were 
eligible for treatment, but had not been treated, and those who reported treatment in the 
previous 6-months. For participants who reported HCV treatment, we assumed that treatment 
occurred halfway between visits and contributed the corresponding amount of person-time. The 
numerator was the number of participants who were treated each year of follow-up, totaling 488 
participants over the 2011-2019 study period.  
For our primary analysis, we used Poisson regression analysis to calculate incidence rate ratios 
of HCV treatment uptake stratified by the three time-periods to understand predictors of HCV 
treatment uptake in each era. Variables considered for the final model included 
sociodemographic characteristics, health-related variables, and drug use practices. To account 
for temporality between healthcare utilization and HCV treatment, we lagged the outpatient 
medical visit by one study visit so that it reflects a participant’s healthcare utilization 6-12 
months before they reported being treated for HCV. Variables considered for the final model 
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were based on a priori knowledge of factors associated with HCV treatment uptake or had p-
values <0.1 in the univariable analysis.   
Finally, because the most recent enrollment cohort had less follow-up than prior cohorts, we 
conducted sensitivity analyses for the DAA-era and calculated both the cumulative HCV 
treatment uptake, as well as annual HCV treatment rates for 2015 through 2019, stratified by 
when a participant was recruited into the study, pre-2005, 2005-2008, 2015-2018. 
Subsequently, we repeated the Poisson regression for the late DAA-era (2017-2019), to 
compare how predictors of HCV treatment uptake varied by enrollment period. 
 
RESULTS 
Characteristics of Study Population 
Characteristics of the 1,146 participants included in the study are presented in Table 1. Overall, 
the median age was 52.7 years (IQR: 47.2, 57.3), 69% (n=791) were male, and 83.3% (n=955) 
were Black. Of the 1,146 participants with evidence of prior HCV infection, 50% (N=572) 
reported receiving any treatment for HCV. Among those who were treated, 14.7% (N=84) were 
prior to the analysis and 85.3% (N=488) reported being treated during follow-up. Among the 488 
participants, nearly half had at least a high school education or equivalency (n=233, 47.7%), 
73% had cirrhosis (n=356, 73.0%), and 64.5% (n=314) had injected drugs within the 6-months 
prior to entering the study. Of those who were not treated for HCV (N=574), 70.4% (n=404) had 
HCV mono-infection and 22% had no or mild fibrosis (n=126). Finally, the 84 treated prior to the 
analysis were more likely to be HIV/HCV coinfected with an undetectable HIV viral load (n=38, 
45.2%), as well as, have at least two other chronic diseases (n=59, 70.2%), compared to those 
who were never treated or treated during follow-up.  
Temporal Changes of HCV Treatment Uptake 
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Overall, HCV treatment uptake improved throughout the study period. Figure 1 shows that 
cumulative treatment uptake increased from 15% of the population being treated in 2011 to 70% 
in 2019, a 4.7-fold increase. Among those who were treatment naïve at entry into the 
study/analysis, the rate of HCV treatment uptake was lowest in the interferon-era, ranging from 
0.08 per 100 person-years in 2011 to 0.44 per 100 person-years in 2013 (Figure 2). There was 
a 3.9-fold increase between 2014 (0.68 per 100) and 2015 (2.68 per 100 person-years), the first 
two years of the early DAA-era. After an initial peak in 2015, the treatment rate dropped until 
2017 after which point there was a 3.4-fold increase to reach 6.63 per 100 person-years in 
2019. 
Characteristics of Participants Receiving HCV Treatment during Study Period 
Characteristics of the 488 participants who were treated during the study period are presented 
in Table 2, stratified by time-period. Only 6.5% (N=54) of those with visits in the interferon-era 
reported HCV treatment. Of those who did, 85.2% (n=46) were Black, 16.7% (n=9) reported any 
recent non-injection drug use, and 79.6% (n=43) did not report any injection drug use in the 
prior 6-months. In terms of healthcare-related characteristics, 46.3% (n=25) had Medicaid, 
51.9% (n=28) were HCV mono-infected, and 68.5% (n=37) had cirrhosis. Roughly one-quarter 
(N=210) of those with visits in the early DAA-era reported being treated for HCV. Characteristics 
of those who were treated were similar to those treated in the interferon-era in terms of injection 
drug use (n=167, 79.5%), being insured through Medicaid (n=98, 46.9%), being HCV mono-
infected (n=106, 50.5%), and having cirrhosis (n=147, 70.0%). However, a larger percentage 
were Black (n=202, 96.2%) and had reported non-injection drug use in the previous 6-months 
(n=48, 22.9%). One-third (N=224) with visits in the late DAA-era were treated for HCV. Of them 
79.9% (n=179) were Black, 45.5% (n=102) reported recent non-injection drug use and 61.4% 
(n=137) reported not injecting drugs in the last 6-months. A larger percentage had Medicaid 
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insurance (n=138, 61.6%) and HCV mono-infection (n=151, 67.4%), but fewer had cirrhosis 
(n=98, 43.8%), compared to the other two treatment eras. 
Associations between Covariates and Rate of HCV Treatment Uptake  
Correlates of HCV treatment uptake for the three time-periods are presented in Table 3. In the 
interferon era, the rate of treatment uptake was 2.81 (95% CI: 1.30, 6.07) times higher among 
those with at least a high school diploma or GED compared to those who had not completed 
high school in the univariable analysis. The association persisted (IRR: 2.69, 95% CI: 1.27, 
5.73) after adjusting for demographics, healthcare utilization, comorbidities, and recent drug 
use. No other factors were significantly associated with HCV treatment uptake for that time-
period.  
In the early DAA-era, Black race (IRR: 3.33, 95% CI: 1.50, 7.43) and having an outpatient visit 
6-12 months before reporting being treated for HCV (IRR: 2.90, 95% CI: 1.78, 4.73) were 
significantly associated with HCV treatment uptake in univariable analysis. The rate of treatment 
uptake also increased with age (IRR: 1.06, 95% CI: 1.04, 1.08), having at least one chronic 
comorbidity (IRR: 1.63, 95% CI: 1.05, 2.52), cirrhosis (IRR: 1.69, 95% CI: 1.19, 2.38), and being 
HIV/HCV coinfected with an undetectable HIV viral load (IRR: 2.10, 95% CI: 1.61, 2.74). In the 
multivariable model, age (IRR: 1.05, 95% CI: 1.02, 1.07), having an outpatient visit (IRR: 2.25, 
95% CI: 1.34, 3.76), having cirrhosis (IRR: 1.64, 95% CI: 1.16, 2.32), and being HIV/HCV 
coinfected with an undetectable HIV viral load (IRR: 1.87, 95% CI: 1.42, 2.48) remained 
significantly associated with having a higher HCV treatment uptake. 
In the later DAA-era, being female (IRR: 0.66, 95% CI: 0.47, 0.93) and injecting drugs daily 
(IRR: 0.60, 95% CI: 0.38, 0.97) were associated with lower HCV treatment uptake, while having 
an outpatient visit 6-12 months before reporting HCV treatment was associated with 2.43 (95% 
CI: 1.58, 3.73) times treatment uptake in univariable analysis. In multivariable analysis, the 
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associations between treatment uptake and being female (IRR: 0.65, 95% CI: 0.45, 0.92) and 
having an outpatient visit (IRR: 2.42, 95% CI: 1.56, 3.77) remained significant. We also found 
that the treatment rate was 65% (95% CI: 0.16, 0.77) lower if the participant was HIV/HCV 
coinfected with a detectable HIV viral load compared to HCV mono-infected participants. 
In sensitivity analyses, we compared treatment uptake by recruitment cohort to ensure that 
treatment uptake was not driven by participants more recently recruited with limited follow-up 
(e.g., from 2015 and 2018). Results showed that treatment uptake was consistent across the 
cohorts (see supplemental materials).  
 
DISCUSSION 
Our study demonstrated that among this population of people who inject drugs (PWID), HCV 
treatment uptake improved from 15% being treated in the interferon-era to 70% in the late DAA-
era. In this cohort, treatment uptake remained <5% for more than two decades.30 However in 
our study, half of the participants reported being treated for HCV over this 9-year period. The 
most dramatic improvement in treatment uptake occurred following the availability of direct 
acting antivirals (DAA). Initially, the increase in HCV treatment was slow, but it increased 
remarkably from 2014 to 2019, likely reflecting the greater number of DAAs available and 
relaxed insurance restrictions over time. However, some barriers to HCV treatment remain in 
this population and in order to achieve ambitious elimination goals, many more will need to be 
treated and these barriers will have to be addressed.   
The observed trends in treatment uptake were consistent with findings in other populations and 
PWID. Overall, in the interferon-era, it was estimated that only 16% of those with HCV infection 
initiated treatment and less than 10% of PWID, specifically.25–28,58 In fact, we found that only 7% 
of those eligible for treatment were treated in the 2011-2013 interferon-era time period. This 
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increased to 25% in the early DAA-era and 35% in the late DAA-era. Those more likely to be 
treated in the early DAA-era were older, had advanced liver disease, and were already engaged 
in the healthcare system. Compared to the other two treatment periods, in the late DAA-era, 
treatment uptake improved among participants with recent drug use and those with mild or no 
liver fibrosis. These trends in treatment uptake are similar to other populations and likely reflect 
the impact of DAA-based therapies, as well as the implementation and relaxation of insurance 
restrictions.31,32,39,59–61  
HCV is a slow progressing, largely asymptomatic, disease.62 It takes 25-30 years for roughly 
30% of those with chronic HCV infection to develop cirrhosis, the most severe stage of 
fibrosis.62 Despite having Medicaid fibrosis restrictions in the later DAA-era, we found that older 
age and having cirrhosis were not predictors of HCV treatment uptake, as they were in the early 
DAA-era. In fact, the percentage of those treated who had mild or no fibrosis more than doubled 
from 19% to 44% between the early and late DAA eras, respectively. There are a few ways to 
explain this observation. First, the fibrosis restriction was unique to Medicaid and 40% of the 
participants treated had either Medicare, private insurance, or insurance through the Veterans 
Administration, which was not subject to the same restrictions. Second, insurance companies 
and treatment guidelines prioritize treatment among those with severe liver fibrosis and non-
decompensated cirrhosis.39,63,64 As a result, those with advanced liver fibrosis would be treated 
first, once DAAs became available. Because these people were successfully treated in the early 
DAA-era, it would decrease the proportion of individuals who were eligible for HCV treatment 
and had cirrhosis in the late DAA-era.  
To achieve HCV elimination among PWID, we must first identify which PWID are not accessing 
HCV treatment and develop strategies to reach them. We found that healthcare utilization was 
the greatest predictor of treatment uptake in the late DAA period. Additionally, our findings 
indicated that daily injection drug use was the main barrier to treatment in the late DAA period. 
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For this study, we did not ask participants why they were not treated for HCV. As a result, we 
cannot definitively conclude why active PWID were not treated as often as former PWID. Poor 
treatment uptake among active PWID is likely a combination of individual and provider-level 
barriers. Provider reluctance to treat people with current or former substance use was a barrier 
in the interferon period, with providers citing fear of poor treatment adherence or reinfection.65,66 
Despite interferon and DAA-era studies showing similar cure rates among PWID with recent or 
active drug use compared to those not using drugs, some providers are still reticent about 
treating active PWID.66–68 It is possible that provider stigma associated with active drug use 
remains a persistent barrier among active PWID who are motivated to be treated today. In terms 
of individual-level barriers, like in the interferon-era, it is also possible that HCV treatment is a 
lower priority when a person is actively injecting drugs with high frequency.29 These 
uncertainties highlight the need for future investigations to understand non-treatment among this 
group.  
Our study is not without limitations. First, given the longitudinal nature of the study, selection 
bias due to losses to follow-up could be a concern. In particular, since we included participants 
from all recruitment cohorts in this analysis, there is a potential for survivor bias. For example, 
participants who were older or HIV/HCV coinfected are more likely to experience HCV-related 
mortality. As a result, our sample may include participants who were healthier than the larger 
PWID community. However, we do not think survivor bias will threaten the internal validity of our 
results, as our sensitivity analysis showed treatment uptake was consistent across recruitment 
cohorts and our main findings are consistent to those of other studies. Second, other than HIV 
and HCV status and liver fibrosis, other variables, including our outcome, HCV treatment, are 
based on self-report. We do not anticipate that this will result in biased associations, as other 
studies have validated self-reported treatment initiation with HCV RNA testing.69 Finally, 
Maryland relaxed its Medicaid’s fibrosis restriction in 2019, which was also the end of our study 
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period. As a result, our study did not have sufficient follow-up time after its implementation to 
capture changes in treatment uptake resulting from the modification. We expect that treatment 
uptake will continue to improve because of it. 
In conclusion, it was encouraging that half of this population of current and former PWID had 
been treated for HCV, of which, 85% was between 2011-2019. However, we did identify 
characteristics associated with not being treated, namely daily injection drug use and poor 
healthcare utilization. Both were barriers in the interferon-era and persist today. Initiating HCV 
treatment among this population is and will continue to be difficult for a variety of reasons. 
However, HCV elimination goals are unachievable without doing so. Our work highlights the 
need for future studies to identify which specific individual-level barriers are preventing these 
subgroups from initiating treatment. These results can, in turn, be used to inform interventions 
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Table 1. Characteristics of 1,146 HCV-antibody positive participants by self-reported HCV treatment status anytime from 2011-2019 
  Never treated for HCV Treated during follow-up Treated prior to analysis p-value 
N 574 488 84   
Demographic Characteristics         
Age (year), median (IQR) 52.1 (45.5, 56.5) 53.5 (48.9, 57.9) 53.4 (47.0, 59.2) <0.01 
Female sex 209 (36.4%) 130 (26.6%) 16 (19.0%) <0.01 
Black race 464 (80.8%) 427 (87.5%) 64 (76.2%) <0.01 
Education level ≥high school diploma  230 (40.2%) 233 (47.7%) 30 (35.7%) 0.02 
Homeless or displaced1 107 (18.7%) 69 (14.1%) 15 (17.9%) 0.13 
Drug Use Practices1         
Any non-injection drug use2  208 (36.2%) 166 (34.0%) 36 (42.9%) 0.28 
Frequency of injection drug use         
   None 337 (58.9%) 314 (64.5%) 43 (51.2%) 
0.01    Less than daily 119 (20.8%) 103 (21.1%) 17 (20.2%) 
   Daily 116 (20.3%) 70 (14.4%) 24 (28.6%) 
Any alcohol use  309 (54.0%) 260 (53.4%) 37 (44.0%) 0.23 
Visited syringe services program  100 (17.5%) 62 (12.7%) 17 (20.2%) 0.05 
Prescribed medication for OUD3,4 223 (38.9%) 167 (34.2%) 30 (35.7%) 0.29 
Co-Morbidities and Healthcare Utilization         
Type of health insurance1         
    Medical Assistance 288 (50.3%) 233 (47.9%) 40 (48.2%) 
0.52     Medicare or other insurance5 238 (41.6%) 216 (44.4%) 40 (48.2%) 
    Uninsured 46 (8.0%) 37 (7.6%) 3 (3.6%) 
Visited the emergency department1 185 (32.3%) 129 (26.4%) 33 (39.3%) 0.02 
At least one outpatient visit1 394 (68.8%) 357 (73.3%) 66 (78.6%) 0.09 
HIV status/HIV viral suppression6         
   HCV mono-infected 404 (70.4%) 287 (58.8%) 39 (46.4%) 
<0.01    Coinfected & undetectable HIV  96 (16.7%) 151 (30.9%) 38 (45.2%) 
   Coinfected & detectable HIV  74 (12.9%) 50 (10.2%) 7 (8.3%) 
Fibrosis score7         
   None or Mild Fibrosis 126 (22.0%) 101 (20.7%) 14 (16.7%) 
0.18    Significant Fibrosis  50 (8.7%) 31 (6.4%) 11 (13.1%) 
   Cirrhosis  398 (69.3%) 356 (73.0%) 59 (70.2%) 
Health index8         
   No comorbidities 116 (20.2%) 101 (20.7%) 17 (20.2%) 
0.13    1 comorbidity 105 (18.3%) 103 (21.1%) 8 (9.5%) 
   ≥2 comorbidities 353 (61.5%) 284 (58.2%) 59 (70.2%) 
Depressive symptoms (CESD>23)1 154 (26.9%) 115 (23.6%) 23 (27.4%) 0.43 
Recruitment Cohort         
1988-1989 192 (33.4%) 166 (34.0%) 21 (25.0%) 
<0.01 
1994-19959 94 (16.4%) 70 (14.3%) 5 (6.0%) 
2005-2008 176 (30.7%) 144 (29.5%) 22 (26.2%) 
2015-2018 112 (19.5%) 108 (22.1%) 36 (42.9%) 
1Reflective of 6 months prior to study visit 
2Includes smoking crack or heroin 
3Prior to 2014, participants who reported seeking substance use treatment were asked if it was part of a methadone maintenance program only. 
Starting in 2014, all participants were asked if they were prescribed methadone, buprenorphine or Naltrexone 
4OUD is abbreviation of opioid use disorder 
5Insurances included were Medicare, private insurance, insurance through the Affordable Care Act, Veterans Administration, Ryan White, or any 
other type 
6Viral suppression is defined as ≤50 copies per mL 
7None or mild fibrosis defined as <8 kPa, significant fibrosis defined as 8-12.3 kPa, cirrhosis defined as ≥12.3 kPa 
8Based on if a participant reported ever being diagnosed or diagnosed in previous 6-months for any of the following: diabetes (high blood sugar), 
seizures (epilepsy or convulsions), high cholesterol, hypertension (high blood pressure), stroke, kidney (kidney) disease or failure, chronic lung 
disease (asthma, COPD, emphysema, not pneumonia), depression, anxiety or panic disorder, bipolar disorder, schizophrenia/schizoaffective 
disorder   








DAA Era with Strict Restrictions 
(2014-2016) 
Later Availability of DAAs 
(2017-2019) 
p-value 
N 54 (6.5%)2 210 (25.1%)2 224 (34.8%)2   
Demographic Characteristics        
Age (year), median (IQR)   54.1 (49.1, 57.9) 58.2 (54.2, 62.7) 56.9 (51.3, 61.6) <0.01 
Female sex 14 (25.9%) 53 (25.2%) 63 (28.1%) 0.79 
Black race 46 (85.2%) 202 (96.2%) 179 (79.9%) <0.01 
≥High school diploma  29 (53.7%) 95 (45.2%) 109 (48.7%) 0.50 
Homeless or displaced3 7 (13.0%) 15 (7.1%) 23 (10.3%) 0.32 
Drug Use Practices3        
Any non-injection drug use4 9 (16.7%) 48 (22.9%) 102 (45.5%) <0.01 
Frequency of injection use         
   None 43 (79.6%) 167 (79.5%) 137 (61.4%) 
<0.01    Less than daily 8 (14.8%) 23 (11.0%) 47 (21.1%) 
   Daily 3 (5.6%) 20 (9.5%) 39 (17.5%) 
Any alcohol use 20 (37.0%) 90 (42.9%) 112 (50.2%) 0.13 
Visited syringe services program 2 (3.7%) 18 (8.6%) 44 (19.7%) <0.01 
Prescribed medication for OUD5,6 15 (27.8%) 96 (45.7%) 140 (62.5%) <0.01 
Co-Morbidities and Healthcare Utilization        
Type of health insurance3         
   Medical Assistance 25 (46.3%) 98 (46.9%) 138 (61.6%) 
<0.01    Medicare or other insurance7 26 (48.1%) 109 (52.2%) 85 (37.9%) 
   Uninsured 3 (5.6%) 2 (1.0%) 1 (0.4%) 
Emergency department visit3 12 (22.2%) 56 (26.7%) 66 (29.5%) 0.53 
Outpatient visit last 6-12 months 16 (76.2%) 166 (89.2%) 153 (83.2%) 0.11 
HIV status/HIV viral suppression8        
   HCV mono-infected 28 (51.9%) 106 (50.5%) 151 (67.4%) 
<0.01    Coinfected & undetectable HIV 23 (42.6%) 91 (43.3%) 60 (26.8%) 
   Coinfected & detectable HIV 3 (5.6%) 13 (6.2%) 13 (5.8%) 
Liver fibrosis9         
   None or mild fibrosis 17 (31.5%) 40 (19.0%) 98 (43.8%) 
<0.01    Significant fibrosis 0 (0.0%) 23 (11.0%) 28 (12.5%) 
   Cirrhosis 37 (68.5%) 147 (70.0%) 98 (43.8%) 
Health index10        
   No comorbidities 6 (11.1%) 31 (14.8%) 36 (16.1%) 
0.12    1 comorbidity 10 (18.5%) 60 (28.6%) 43 (19.2%) 
   ≥2 comorbidities 38 (70.4%) 119 (56.7%) 145 (64.7%) 
Depressive symptoms (CESD>23)3 17 (31.5%) 40 (19.0%) 66 (29.6%) 0.02 
Recruitment Cohort        
1988-1989 25 (46.3%) 88 (41.9%) 53 (23.7%) 
<0.01 
1994-199511 8 (14.9%) 35 (16.6%) 27 (12.1%) 
2005-2008 21 (38.9%) 64 (30.5%) 59 (26.3%) 
2015-2018 0 (0.0%) 23 (11.0%) 85 (37.9%) 
18 participants were classified as being treated in 2010 because they reported HCV treatment in previous 6-months at an ALIVE visit in 
January or February 2011 
2Percentage of unique participants who were eligible for HCV treatment in each treatment period: Interferon Era (2011-2013) – 830 
participants; Early DAA Era 2014-2016) – 836 participants; Late DAA Era (2017-2019) – 644 participants 
3Reflective of 6 months prior to study visit 
4Includes smoking crack or heroin 
5Prior to 2014, participants who reported seeking substance use treatment were asked if it was part of a methadone maintenance program 
only. Starting in 2014, all participants were asked if they were prescribed methadone, buprenorphine or Naltrexone 
6OUD is abbreviation of opioid use disorder 
7Insurances included were Medicare, private insurance, insurance through the Affordable Care Act, Veterans Administration, Ryan White, or 
any other type 
8Viral suppression is defined as ≤50 copies per mL 
9None or mild fibrosis defined as <8 kPa, significant fibrosis defined as 8-12.3 kPa, cirrhosis defined as ≥12.3 kPa 
10Based on if a participant reported ever being diagnosed or diagnosed in previous 6-months for any of the following: diabetes (high blood 
sugar), seizures (epilepsy or convulsions), high cholesterol, hypertension (high blood pressure), stroke, kidney (kidney) disease or failure, 
chronic lung disease (asthma, COPD, emphysema, not pneumonia), depression, anxiety or panic disorder, bipolar disorder, 
schizophrenia/schizoaffective disorder   
11Participants recruited in 1998 (N=26) were combined with the participants recruited 1994-1995 (N=44) 
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Table 3. Correlates of HCV treatment uptake by HCV treatment time-period among ALIVE participants, Baltimore MD, 2011-2019 
  Interferon Era (2011-2013) DAA Era with Strict Restrictions (2014-2016) Later Availability of DAAs (2017-2019) 
Characteristic Unadjusted IRR (95% CI) Adjusted IRR (95% CI) Unadjusted IRR (95% CI) Adjusted IRR (95% CI) Unadjusted IRR (95% CI) Adjusted IRR (95% CI) 
Age (year) 0.99 (0.94, 1.03) 0.99 (0.95, 1.04) 1.06 (1.04, 1.08) 1.05 (1.02, 1.07) 1.01 (0.99, 1.02) 0.99 (0.97, 1.01) 
Participant's sex        
   Male REF REF REF REF REF REF 
   Female 1.13 (0.52, 2.44) 1.18 (0.54, 2.57) 0.75 (0.56, 1.02) 0.76 (0.56, 1.03) 0.66 (0.47, 0.93) 0.65 (0.45, 0.92) 
Participant's race       
   non-Black REF REF REF REF REF REF 
   Black 0.56 (0.19, 1.61) 0.63 (0.17, 2.32) 3.33 (1.50, 7.43) 2.00 (0.88, 4.55) 0.96 (0.65, 1.42) 1.07 (0.64, 1.77) 
≥High school diploma       
   No REF REF REF REF REF REF 
   Yes 2.81 (1.30, 6.07) 2.69 (1.27, 5.73) 1.29 (1.00, 1.67) 1.29 (1.00, 1.66) 1.35 (1.00, 1.81) 1.29 (0.94, 1.78) 
Frequency of injection drug use1       
   None REF REF REF REF REF REF 
   Less than daily 1.20 (0.46, 3.16) 1.23 (0.46, 3.32) 0.66 (0.40, 1.07) 0.75 (0.46, 1.21) 1.03 (0.69, 1.53) 1.08 (0.72, 1.63) 
   Daily 0.41 (0.06, 3.03) 0.51 (0.07, 3.60) 0.71 (0.42, 1.18) 0.88 (0.53, 1.47) 0.60 (0.38, 0.97) 0.66 (0.41, 1.06) 
Prescribed medication for OUD1,2,3       
   No REF  REF  REF  
   Yes 1.47 (0.68, 3.18)  0.84 (0.64, 1.10)  1.11 (0.82, 1.51)  
Type of health insurance1       
   Medical Assistance REF  REF  REF  
   Medicare or other insurance4 1.36 (0.61, 3.04)  1.23 (0.93, 1.64)  1.10 (0.81, 1.49)  
   Uninsured 1.22 (0.26, 5.69)  0.36 (0.09, 1.49)  0.48 (0.15, 1.59)  
Outpatient visit last 6-12 months       
   No REF REF REF REF REF REF 
   Yes 1.61 (0.66, 3.94) 1.39 (0.54, 3.61) 2.90 (1.78, 4.73) 2.25 (1.34, 3.76) 2.43 (1.58, 3.73) 2.42 (1.56, 3.77) 
HIV status/HIV viral suppression5       
   HCV mono-Infected REF REF REF REF REF REF 
   Coinfected & undetectable HIV 1.81 (0.83, 3.93) 1.81 (0.79, 4.13) 2.10 (1.61, 2.74) 1.87 (1.42, 2.48) 1.50 (1.06, 2.13) 1.34 (0.93, 1.92) 
   Coinfected & detectable HIV 0.77 (0.18, 3.37) 0.84 (0.20, 3.58) 1.07 (0.61, 1.86) 1.28 (0.73, 2.24) 0.36 (0.17, 0.77) 0.35 (0.16, 0.77) 
Liver fibrosis6       
   None or Mild Fibrosis REF REF REF REF REF REF 
   Significant Fibrosis 0.33 (0.04, 2.57) 0.32 (0.04, 2.51) 1.07 (0.61, 1.87) 0.98 (0.56, 1.74) 0.80 (0.48, 1.34) 0.73 (0.43, 1.24) 
   Cirrhosis 0.89 (0.42, 1.89) 0.91 (0.43, 1.95) 1.69 (1.19, 2.38) 1.64 (1.16, 2.32) 0.95 (0.69, 1.30) 0.89 (0.64, 1.23) 
Health index7       
   No comorbidities REF  REF  REF  
   1 comorbidity 2.43 (0.63, 9.41)  1.63 (1.05, 2.52)  1.18 (0.73, 1.91)  
   ≥2 comorbidities 2.39 (0.71, 8.08)  1.18 (0.80, 1.75)  1.07 (0.72, 1.60)  
1Reflective of 6 months prior to study visit  
2Prior to 2014, participants who reported seeking substance use treatment were asked if it was part of a methadone maintenance program only. Starting in 2014, all participants were asked if they were 
prescribed methadone, buprenorphine or Naltrexone 
3OUD is abbreviation of opioid use disorder 
4Insurances included were Medicare, private insurance, insurance through the Affordable Care Act, Veterans Administration, Ryan White, or any other type 
5Viral suppression is defined as ≤50 copies per mL 
6None or mild fibrosis defined as <8 kPa, significant fibrosis defined as 8-12.3 kPa, cirrhosis defined as ≥12.3 kPa 
7Based on if a participant reported ever being diagnosed or diagnosed in previous 6-months for any of the following: diabetes (high blood sugar), seizures (epilepsy or convulsions), high cholesterol, 
hypertension (high blood pressure), stroke, kidney (kidney) disease or failure, chronic lung disease (asthma, COPD, emphysema, not pneumonia), depression, anxiety or panic disorder, bipolar 




Supplemental Table 1. Correlates of HCV treatment uptake by ALIVE cohort in the later DAA-era, Baltimore MD, 2017-2019 
  Pre-2005 Cohort 2005-2008 Cohort 2015-2018 Cohort 
Characteristic Unadjusted IRR (95% CI) Adjusted IRR (95% CI) Unadjusted IRR (95% CI) Adjusted IRR (95% CI) Unadjusted IRR (95% CI) Adjusted IRR (95% CI) 
Age (year) 1.02 (0.98, 1.06) 0.98 (0.94, 1.03) 1.01 (0.97, 1.04) 0.99 (0.95, 1.03) 1.01 (0.98, 1.04) 1.01 (0.97, 1.05) 
Participant's sex        
   Male REF REF REF REF REF REF 
   Female 0.64 (0.37, 1.11) 0.61 (0.35, 1.07) 0.43 (0.23, 0.82) 0.47 (0.23, 0.93) 1.14 (0.65, 2.00) 1.06 (0.59, 1.90) 
Participant's race       
   Non-Black REF REF REF REF REF REF 
   Black 2.26 (0.57, 8.94) 3.02 (0.71, 12.90) 1.06 (0.54, 2.10) 1.40 (0.63, 3.10) 0.84 (0.49, 1.46) 0.58 (0.25, 1.35) 
≥High school diploma       
   No REF REF REF REF REF REF 
   Yes 1.22 (0.76, 1.96) 1.34 (0.80, 2.24) 1.85 (1.07, 3.20) 1.81 (0.97, 3.26) 0.98 (0.57, 1.67) 0.92 (0.52, 1.65) 
Frequency of injection drug1       
   None REF REF REF REF REF REF 
   Less than daily 1.16 (0.54, 2.49) 1.07 (0.48, 2.41) 0.79 (0.37, 1.72) 0.95 (0.43, 2.13) 0.72 (0.40, 1.29) 0.83 (0.45, 1.50) 
   Daily 0.94 (0.41, 2.15) 0.99 (0.41, 2.35) 0.85 (0.38, 1.91) 1.23 (0.56, 2.72) 0.21 (0.09, 0.49) 0.21 (0.09, 0.51) 
Prescribed medication for OUD1,2,3       
   No REF  REF  REF  
   Yes 0.97 (0.60, 1.56)  1.08 (0.61, 1.94)  1.30 (0.71, 2.40)  
Type of health insurance1       
   Medical Assistance REF  REF  REF  
   Medicare or other insurance4 0.89 (0.55, 1.43)  1.49 (0.85, 2.60)  1.16 (0.64, 2.10)  
   Uninsured 0.29 (0.04, 2.43)  0.62 (0.09, 4.27)  0.85 (0.10, 7.00)  
Outpatient visit last 6-12 months       
   No REF REF REF REF REF REF 
   Yes 8.89 (2.79, 28.92) 10.15 (3.13, 32.87) 1.37 (0.71, 2.66) 1.39 (0.68, 2.84) 1.87 (0.94, 3.74) 1.66 (0.77, 3.60) 
HIV status/HIV viral suppression5       
   HCV Mono-Infected REF REF REF REF REF REF 
   Coinfected & undetectable HIV 1.52 (0.87, 2.65) 1.29 (0.72, 2.31) 1.87 (1.04, 3.38) 1.97 (1.05, 3.70) 1.26 (0.62, 2.58) 1.46 (0.65, 3.31) 
   Coinfected & detectable HIV 0.61 (0.20, 1.82) 0.56 (0.18, 1.77) 0.26 (0.06, 1.10) 0.30 (0.07, 1.31) 0.33 (0.08, 1.46) 0.35 (0.08, 1.50) 
Liver fibrosis6       
   None or Mild Fibrosis REF REF REF REF REF REF 
   Significant Fibrosis 1.07 (0.49, 2.31) 0.86 (0.38, 1.98) 0.60 (0.22, 1.64) 0.49 (0.18, 1.35) 0.77 (0.31, 1.90) 0.73 (0.29, 1.86) 
   Cirrhosis 0.70 (0.43, 1.16) 0.65 (0.39, 1.10) 1.18 (0.67, 2.09) 1.10 (0.63, 1.91) 1.25 (0.70, 2.23) 1.18 (0.63, 2.23) 
Health index7       
   No comorbidities REF  REF  REF  
   1 comorbidity 0.86 (0.41, 1.82)  1.64 (0.71, 3.76)  1.24 (0.49, 3.10)  
   ≥2 comorbidities 0.90 (0.48, 1.69)  1.17 (0.57, 2.39)  1.18 (0.58, 2.41)  
1Reflective of 6 months prior to study visit 
2Prior to 2014, participants who reported seeking substance use treatment were asked if it was part of a methadone maintenance program only. Starting in 2014, all participants were asked if they were 
prescribed methadone, buprenorphine or Naltrexone 
3OUD is abbreviation of opioid use disorder 
4Insurances included were Medicare, private insurance, insurance through the Affordable Care Act, Veterans Administration, Ryan White, or any other type 
5Viral suppression is defined as ≤50 copies per mL 
6None or mild fibrosis defined as <8 kPa, significant fibrosis defined as 8-12.3 kPa, cirrhosis defined as ≥12.3 kPa 
7Based on if a participant reported ever being diagnosed or diagnosed in previous 6-months for any of the following: diabetes (high blood sugar), seizures (epilepsy or convulsions), high cholesterol, 
hypertension (high blood pressure), stroke, kidney (kidney) disease or failure, chronic lung disease (asthma, COPD, emphysema, not pneumonia), depression, anxiety or panic disorder, bipolar 


















































































































































































Supplemental Figure 1. Cumulative HCV treatment uptake among ALIVE 
participants by recruitment cohort, Baltimore MD, 2015-2019




















































Supplemental Figure 2. Annual rate of HCV treatment uptake among ALIVE 
participants by cohort, Baltimore MD, 2015-2019
Participants recruited pre-2005 Participants recruited 2005-2008 Participants recruited 2015-2018
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Chapter 5. Conclusions  
 
In 2014, direct acting antiviral (DAA) agents became available and transformed hepatitis C virus 
(HCV) treatment. In the era of DAA therapies, efforts have been made to improve treatment 
uptake for HCV among people who inject drugs (PWID). While treatment uptake has, 
admittedly, improved among some PWID, the incidence of acute HCV infections has more than 
quadrupled between 2010 and 2018.1 This indicates that there is still sufficient circulation of 
HCV within the PWID community reflecting that not enough PWID have been treated to curtail 
transmission. Studies that have sought to identify barriers to DAA treatment among PWID have 
largely focused on PWID who are either already engaged in healthcare or harm reduction 
services that facilitate HCV testing or care.2–7 As a result, our knowledge base may not reflect 
the true burden of HCV, treatment need, and barriers within important groups of PWID who are 
perpetuating ongoing transmission. In this study, we used a multi-pronged approach to 
understand how treatment uptake has changed from the era of interferon-based therapies to the 
modern DAA-era of HCV therapy and identify subgroups of PWID who have not been treated to 
date. Furthermore, we sought to understand the extent to which specific barriers from the 
interferon-era persist today, how barriers from the interferon-era may be facilitators in the DAA-
era, and emergent barriers specific to the DAA-era.  
 
Summary of Findings 
In Aim 1, we explored changes in treatment penetration throughout Baltimore City and Baltimore 
County by comparing the spatial distribution of HCV treatment need in three timepoints: 
interferon-era (2006-2007), early DAA-era (2015-2016), and late DAA-era (2017-2018). To do 
this, we identified statistically significant spatial clusters of higher than expected rates of HCV 
viremia, which was used as an indicator for treatment need.  Finally, we characterized these 
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areas to help to understand whether clusters of HCV treatment need were explained best by 
characteristics of the individuals with HCV or the neighborhoods themselves. Overall, we found 
that the proportion of HCV viremia per Census tract declined significantly over the three study 
periods. There median proportion of viremia participants decreased from 83% in the interferon-
era, 64% in the early DAA-era and a 39% in the later DAA time-period. Results from our cluster 
detection analysis identified a single cluster in the interferon-era (2006-2007) and two clusters in 
the early DAA-era (2015-2016). The interferon-era cluster was in Census tracts where the 
percentage of viremic participants was greater than 91% and were more likely to be in the most 
deprived neighborhoods. The two clusters in the early DAA-era were located in East and West 
Baltimore and we found that neighborhood deprivation, as well as individual race, were the 
strongest predictors of being in one of the clusters. However, we failed to identify any clusters in 
the later DAA-era. This study showed that by the late DAA-era, HCV treatment had penetrated 
all parts of the city. However, despite this, results also showed that treatment penetration was 
slower in areas of higher neighborhood deprivation and remains low in some places today. This 
signifies a need to investigate individual-level barriers that may explain this finding.  
Aims 2 and 3 focused on individual-level barriers to HCV treatment. In Aim 2, we examined 
differences in HCV knowledge among 826 current and former PWID recruited in 2015-2018, by 
HIV and HCV status. Knowledge questions focused on modes of transmission, natural history, 
and treatment. We found that 23% of the participants had high knowledge of HCV transmission, 
31% had high knowledge of HCV natural history, and 78% had high knowledge of HCV 
treatment. Almost all participants (>97%) were aware of which injection practices could result in 
transmission of HCV. Additionally, almost all participants knew that HCV negatively affects a 
person’s liver (95%), but that most people were asymptomatic (97%). Moreover, most persons 
(62%) were aware of oral therapies for DAAs. However, knowledge of DAA medications did vary 
by HIV/HCV status with the highest knowledge levels among HIV/HCV coinfected individuals 
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(77%), followed by HCV mono-infected individuals (70%), and, finally, HCV negative 
participants (41%). Additionally, less than two-thirds of the participants were aware that DAA 
treatment did not have severe side effects. Overall, there was variability in knowledge of HCV 
treatment by HIV and HCV status. Compared to HCV mono-infected participants, the odds of 
having a high treatment knowledge score among HCV negative and HIV/HCV coinfected 
participants was 0.22 (95% CI: 0.14, 0.36) and 1.40 (95% CI: 0.67, 2.91), respectively, adjusting 
for demographics, drug use, healthcare utilization, and social networks size. Moreover, among 
HCV-positive participants, we found that those who were aware of their HCV status prior to the 
ALIVE baseline visit had 3-times the odds of a high treatment score, compared to those who 
were diagnosed at baseline study visit. These findings demonstrate that, overall, HCV 
knowledge was high. While participants did not report where they were educated about HCV, 
findings from this study suggest that treatment may be discussed either at the time of or after 
their diagnosis of HCV. This underscores the importance of accurately describing the 
differences between interferon-based therapies and DAAs, as a way to promote HCV treatment.   
In Aim 3, we evaluated temporal changes in treatment uptake among 1,146 HCV-infected 
participants, between 2011 and 2019, to understand how predictors and barriers to HCV 
treatment changed during the interferon and DAA eras. Overall, half of the participants reported 
being treated for HCV, of which, 488 (85%) reported treatment during the 2011-2019 study 
period. We found that treatment uptake improved greatly between the interferon and DAA eras. 
For example, cumulative treatment uptake increased 32% from 2011 until 2014. By comparison, 
it increased 265% from 2014 through 2019. We observed an initial peak in 2015, when the 
treatment rate increased from 0.7 per 100 person-years in 2014 to 2.7 per 100,000 person-
years in 2015. The treatment rate declined slightly afterwards but increased to 6.6 per 100 
person-years, a 129% increase from 2018.  
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The factors that explained treatment uptake also changed overtime. For example, when 
treatment uptake was lowest, in the interferon-era (2011-2013), education level was the only 
predictor of treatment uptake (IRR: 2.73, 95% CI: 1.29, 5.80), likely reflective of the health 
literacy needed to navigate the healthcare system and complicated treatment regimens at the 
time. In the early DAA-era (2014-2016), we found that characteristics of those treated were 
older age (IRR: 1.05, 95% CI: 1.02, 1.07), current engagement in healthcare (IRR: 2.24, 95% 
CI: 1.34, 3.75), and having cirrhosis (IRR: 1.64, 95% CI: 1.16, 2.32), all of which are groups who 
would have been able to circumvent the early insurance restrictions enacted at that time. 
Finally, in the late DAA-era (2017-2019), participants who injected daily (IRR: 0.64, 95% CI: 
0.39, 1.02) or who were HIV/HCV coinfected, but had a detectable HIV viral load (IRR: 0.35, 
95% CI: 0.16, 0.76) had lower treatment rate than their counterparts. However, treatment 
uptake was better if a participant was already engaged in the healthcare system (IRR: 2.42, 
95% CI: 1.56, 3.77). Our study found that treatment uptake has improved among many PWID, 
but it appears that treatment uptake is lower among those who are at highest risk of 
transmission or reinfection. While not surprising, this is concerning and signals that effective 
strategies to help engage these individuals in HCV care should be prioritized.  
 
Strengths and Limitations 
The strengths of our study stem from the fact that this research was nested in the ALIVE study. 
First, the ALIVE study’s recruitment methods aim to achieve representation of the wider PWID 
community, including those who both are and are not engaged in the healthcare system or with 
harm reduction services.8 The changing characteristics of the cohort over the past three 
decades further supports the representativeness of the study participants. It includes diverse 
representation across the spectrum and history of injection drug use in Baltimore City including 
older Black, urban PWID that were associated with the heroin and cocaine epidemics in the 
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1980s and 1990s, as well as, young, white suburban PWID, groups reflecting the current opioid 
epidemic. As one of the longest running community-based cohorts of PWID, there are three 
decades worth of rich data, which supported the longitudinal analyses completed here. Finally, 
we were able to use laboratory confirmation for HCV and HIV status, as well as, fibrosis stage, 
rather than self-report.  
Our study also had several limitations. For Aim 1, some Census tracts had a small number of 
participants, which may limit the generalizability of this aim. While the small number of 
participants in Census tracts is a concern for mapping the crude viremia prevalence, we used 
Bayesian smoothing techniques to calculate the estimated prevalence of HCV viremia, adjusting 
for population size.9,10 Furthermore, SaTScan is not impacted by a small number of cases 
because it considers different aggregations of data via the continuously moving window.11,12 
Another limitation is that we used reported residential addresses, which may not be where a 
person lives or sleeps, given the transient population. If so, our results may misrepresent the 
areas where treatment has penetrated in Baltimore. For Aim 2, we do not ask where participants 
were educated about HCV. We attempted to understand if education was happening before or 
after diagnosis by performing a sensitivity analysis, where we stratified by whether a participant 
was aware of their HCV infection prior to their baseline study visit or if they diagnosed through 
HCV testing done at ALIVE. This still limits out ability to draw conclusions about when a person 
was educated (i.e. at the time of testing) or by whom; however, this was not the primary focus of 
the aim. For Aim 3, HCV treatment, our outcome, was based on self-report and not confirmed 
with medical record review. As a result, there may have been underreporting of the number of 
people treated, particularly during the interferon-era when the treatment regimen was 
complicated. Also, self-reported HCV treatment was only asked to a subset of participants who 
stated that they were aware treatment was available and that they would agree to start 
treatment, when offered by an HCV provider. By contrast, in the DAA-era, all participants were 
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asked about HCV treatment. This skip pattern in the survey could have also contributed to 
undercounting the number of people who were treated in the interferon-era. However, since 
ALIVE studies in the interferon-era also reported that a small number of participants were 
treated during that time, it is unlikely to affect our findings.13 Finally, there are also potential 
limitations given the nature of the study. For example, drug use, comorbidities, and healthcare 
utilization are self-reported. Given that these are sensitive topics, it is possible that participants 
may not accurately report the information. However, an earlier study in ALIVE showed good 
reliability in participant’s self-reported answers.14 Finally, it is possible that the ALIVE study 
population may not be representative of the larger PWID community. Not only do individuals 
need to be enrolled in the study and attend follow-up visits, but as a prospective study, there 
may be losses to follow-up. This is of particular concern for the participants that were recruited 
in the early cohorts and are now aging, and those who were HIV/HCV coinfected, as both 
groups are more likely to have experienced HCV-related morbidity or mortality that could result 
in them leaving the study. This would underestimate the participants with HCV viremia in Aim 1 
and number of participants who were eligible for treatment but never treated in Aim 3. In both 
instances, it may overestimate the extent to which treatment uptake improved. However, results 
from both aims are consistent to findings in other studies.  
  
Public Health Implications and Recommendations for Future Research 
Our study demonstrated that treatment uptake among PWID has improved remarkably since the 
availability of DAAs. Furthermore, we found that treatment has penetrated even the most 
marginalized areas of Baltimore, Maryland. These results are encouraging and likely reflect the 
success and impact of many programs aimed at improving the health of PWID. For example, 
the Affordable Care Act expanded access to healthcare generally, but there were also programs 
specifically designed to improve treatment among PWID. Once treatment became simpler, 
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treatment was expanded into primary care and co-located at services utilized by PWID, like 
substance use treatment facilities that prescribe medication for opioid use disorder.15–18 This not 
only helped to increase the number of providers that were able treat, but also helped make HCV 
treatment more accessible to people outside of the healthcare system. There have also been 
programs that successfully utilized patient navigation, peer support groups with treatment 
experienced PWID, and patient incentives.19–24 Additionally, efforts were made to educate the 
providers, patients, and the public about DAAs. For instance, the CDC and pharmaceutical 
companies released formal education materials, PWID could also learn about DAAs through 
word-of-mouth, anywhere HCV testing is offered, at harm reduction services, healthcare offices 
or emergency departments. Our results stress the importance of not only continuing these 
efforts but also the need for future research to expand their reach.   
However, given that transmission of HCV is ongoing, subgroups of PWID still fail to access HCV 
treatment for either initial infection or reinfection. Without improving treatment uptake among 
these groups, we will not achieve the HCV elimination goals. Furthermore, if left unaddressed, 
HCV-related mortality rates or comorbidities could increase in 20-30 years, similar to those who 
were infected in the 1980s and 1990s. We found the subgroup least likely to access HCV 
treatment were those who injected drugs daily, which is consistent with other studies in both the 
interferon-era and DAA-era.3,13,25–28 There are structural, provider and individual-level barriers 
preventing even motivated PWID from being treated. For example, concerns with how to pay for 
treatment could impact both provider and patient willingness to be treated.7,29–31 Motivated 
individuals may experience provider unwillingness due to stigma associated with active drug 
use or inconsistent engagement in healthcare.7,30–33 Provider education can stress that cure 
rates are not affected by drug use, which may help assuage some reluctant providers but not 
all. Finally, most people do not experience HCV-related symptoms and may not prioritize 
treatment over more immediate concerns, like housing, employment, or food insecurity.13,23,25 
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Engaging this group of PWID will be difficult. Our findings stress the need for future studies to 
fully understand specific barriers that this group of PWID experience, which in turn can be used 
to develop innovative strategies to engage them.     
HCV knowledge is a critical but modifiable factor that can improve treatment uptake among all 
PWID. Knowledge of the advancements of interferon-free, DAAs may motivate some PWID to 
be treated but misinformation regarding DAAs could be the reason some PWID choose not to 
initiate treatment. The most striking differences between DAAs and interferon-based therapies, 
are the higher cure rates, reduced pill burden, shorter duration of treatment, and minimal 
adverse events.34–38 Our findings show that overall knowledge of HCV has improved in this 
population, but some residual misinformation about interferon-based therapies remains.13 In 
particular, participants were aware that HCV is curable, but awareness the other key features of 
DAAs was mixed and particularly low among HCV negative PWID. This is consistent with 
another recent study among PWID in opioid treatment programs.3 While we were unable to 
identify where PWID were educated about HCV and if treatment motivation varied by HCV 
knowledge level, it does warrant future investigation. This could be an important area of 
research because the quality of HCV education may vary between locations. Additionally, while 
most substance use treatment facilities that prescribe medication for opioid use disorder can 
educate consumers about HCV, there is evidence to show that many PWID do not access those 
HCV services.23,39,40 Our findings did, however, identify HCV knowledge deficits that can be 
addressed more immediately to ensure that information about DAAs is relayed correctly.       
 
Summary 
Presently, HCV elimination is unachievable in the United States. The number of acute cases of 
HCV infections has increased for almost 10-years, with little indication that it is slowing. 
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Improving HCV treatment among PWID is key to decreasing HCV transmission. This study 
established knowledge in understanding how treatment uptake among PWID has changed from 
the interferon-era into direct acting antiviral (DAA) era. Additionally, we were able to provide 
insight into characteristics of PWID who are at-risk of not accessing HCV treatment now and 
potential barriers that may explain poor treatment uptake among some today. It highlights not 
only the progress that has been made to ensure equitable access to HCV treatment, but also 
raise awareness to where gaps may remain. Our study results can guide future research into 
the development of effective of strategies to improve treatment uptake and can also be used to 
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